Hyperglycemia, Risk of Subsequent Stroke, and Efficacy of Dual Antiplatelet Therapy: A Post Hoc Analysis of the POINT Trial

Brian Mac Grory, MB BCh BAO, MRCP; Jonathan P. Piccini, MD, MHS; Shadi Yaghi, MD; Sven Poli, MD; Adam De Havenon, MD; Sara K. Rostanski, MD; Martin Weiss, MD; Ying Xian, MD, PhD; S. Claiborne Johnston, MD, PhD; Wuwei Feng, MD, MS

BACKGROUND: One-quarter of all strokes are subsequent events. It is not known whether higher levels of blood glucose are associated with an increased risk of subsequent stroke after high-risk transient ischemic attack or minor ischemic stroke.

METHODS AND RESULTS: We performed a secondary analysis of the POINT (Platelet Oriented Inhibition in New TIA and Minor Ischemic Stroke) trial to evaluate the relationship between serum glucose hyperglycemia (≥180 mg/dL) versus normoglycemia (<180 mg/dL) before enrollment in the trial and outcomes at 90 days. The primary end point was subsequent ischemic stroke modeled by a multivariable Cox model with adjustment for age, sex, race, ethnicity, study treatment assignment, index event, and key comorbidities. Of 4878 patients included in this study, 267 had a recurrent stroke. There was a higher hazard of subsequent stroke in patients with hyperglycemia compared with normoglycemia (adjusted hazard ratio [HR], 1.50 [95% CI, 1.05–2.14]). Treatment with dual antiplatelet therapy was not associated with a reduced hazard of subsequent stroke in patients with hyperglycemia (HR, 1.18 [95% CI, 0.69–2.03]), though the wide confidence interval does not exclude a treatment effect. When modeled as a continuous variable, there was evidence of a nonlinear association between serum glucose and the hazard of subsequent stroke (P<0.001).

CONCLUSIONS: Hyperglycemia on presentation is associated with an increased risk of subsequent ischemic stroke after high-risk transient ischemic attack or minor stroke. A rapid, simple assay of serum glucose may be a useful biomarker to identify patients at particularly high risk of subsequent ischemic stroke.

REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT0099102.

Key Words: antithrombotic therapy ■ clinical trial ■ diabetes ■ hyperglycemia ■ ischemic stroke
stroke. One prior study suggested that stress hyperglycemia (serum glucose indexed against glycosylated albumin) was associated with subsequent stroke. However, it is not known whether serum glucose itself is associated with subsequent stroke risk.

The objective of this study was to determine whether serum glucose measured on presentation to the emergency department is associated with the risk of subsequent ischemic stroke within 90 days after a high-risk TIA or minor ischemic stroke. We hypothesized that elevated admission serum glucose is associated with a higher risk of subsequent stroke.

**METHODS**

This research is based on the National Institute of Neurological Disorders and Stroke’s archived clinical research data sets (POINT [Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial], S. Claiborne Johnston [U01/NS062835]). The data supporting this study are available upon request from the National Institute of Neurological Disorders and Stroke Clinical Research Liaison (CRLiaison@ninds.nih.gov). The code supporting this analysis and the Strengthening the Reporting of OBServational studies in Epidemiology checklist for observational research are included in Data S1. Because this study was performed using a deidentified, publicly available data set, it was deemed exempt from further review by the institutional review board of Duke University School of Medicine (number 00108046).

**Study Design**

We performed a secondary analysis using data from the POINT (Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT00991029). The POINT compared clopidogrel/aspirin to aspirin alone with respect to the primary outcome of a composite of subsequent ischemic stroke, myocardial infarction, or vascular death within 90 days of randomization. It enrolled 4881 patients aged 18 years or older who presented with a high-risk TIA (ABCD² score ≥4) or acute minor ischemic stroke (National Institutes of Health Stroke Scale score ≤3) between May 2010 and December 2017 at 269 hospitals. Patients were excluded if they received intravenous tissue-type plasminogen activator, mechanical thrombectomy, had an indication for anticoagulation, or were planned for carotid endarterectomy.

**Exposure**

The independent variable in this analysis was hyperglycemia. This was defined as a random serum glucose on presentation ≥180 mg/dL (10 mmol/L). The threshold of 180 mg/dL was chosen a priori based on (1) the upper bound of the active control arm of the SHINE (Stroke Hyperglycemia Insulin Network Effort) trial and (2) the upper bound of the serum glucose range recommended from the 2019 Guidelines for the Early Management of Acute Ischemic Stroke. Serum glucose was assayed on presentation per trial protocol and documented before a determination was made on eligibility for the trial. It was recorded in millimoles per liter or milligrams per deciliter and stored pro forma by study investigators. We excluded patients in whom serum glucose level was unavailable.

**End Points**

The primary end point of this analysis was subsequent ischemic stroke. This was collected as a random serum glucose on presentation ≥180 mg/dL (10 mmol/L). The threshold of 180 mg/dL was chosen a priori based on (1) the upper bound of the active control arm of the SHINE (Stroke Hyperglycemia Insulin Network Effort) trial and (2) the upper bound of the serum glucose range recommended from the 2019 Guidelines for the Early Management of Acute Ischemic Stroke. Serum glucose was assayed on presentation per trial protocol and documented before a determination was made on eligibility for the trial. It was recorded in millimoles per liter or milligrams per deciliter and stored pro forma by study investigators. We excluded patients in whom serum glucose level was unavailable.
Power Calculations
Because this study was performed on a data set of fixed size, sample size calculations were not performed in advance of data analysis. Instead, we calculated study power across a range of postulated hazard ratios and group proportions. With the known 267 ischemic stroke events in the data set and assuming 15% of subjects in the exposure (hyperglycemia) group, a Cox proportional hazards regression model would have 99% power to detect a hazard ratio (HR) of 2 between the groups, at an α of 0.05. We determined the study was likely to be adequately powered with study power in the extreme cases ranging from 61% (10% exposed; HR, 1.5) to 99.9% (25% exposed; HR, 2.5). Power calculations were performed using the powerSurvEpi package in R (version 4.03; R Foundation for Statistical Computing, Vienna, Austria).

Statistical Analysis
Our study sample was described using descriptive statistics with mean±SD or median±interquartile range as appropriate for continuous variables and frequencies/counts for categorical variables. Patients with or without hyperglycemia were compared on univariate analysis using the Student t test or Mann-Whitney test for continuous variables and the χ² or Fisher exact test for categorical variables, as appropriate. We compared the rate of subsequent ischemic stroke between patients with and without hyperglycemia on presentation using Kaplan-Meier statistics. The log-rank test was used to compare survival curves between groups.

We constructed a Cox proportional hazards regression model to calculate HRs for the primary end point between those with and without admission hyperglycemia. We adjusted for known predictors of subsequent stroke by including age, biological sex, hypertension, diabetes, coronary artery disease, congestive cardiac failure, tobacco exposure, valvular heart disease, carotid disease, treatment assignment (clopidogrel/aspirin versus placebo/aspirin based on the intent-to-treat analysis), and index event classification (high-risk TIA or acute minor ischemic stroke). Additionally, we chose to include both race and ethnicity in multivariable modeling because each is known to predict subsequent stroke. We tested the assumption of proportional hazards by inspection of Schoenfeld residuals plots. We fitted models containing the interaction terms hyperglycemia*clopidogrel and hyperglycemia*final adjudicated cause. No adjustment was performed in the clopidogrel interaction analysis because we expected equal distribution of covariates across groups. We reported the HRs with 95% CIs for clopidogrel within the stratifications of hyperglycemia or no hyperglycemia and for hyperglycemia within the subdivisions of diabetes or no diabetes and minor stroke or other adjudicated cause. These analyses were repeated for the secondary end points of major hemorrhage and the composite outcome of ischemic stroke, myocardial infarction, or vascular death.

Sensitivity/Subgroup Analyses
We performed several further analyses:

1. We used a continuous measurement of admission serum glucose as the independent variable within a fully adjusted proportional hazards regression model. To explore the potential for nonlinearity between glucose and subsequent stroke, glucose was modeled as a restricted cubic spline. We chose 5 knots within the restricted cubic spline function at the 5%, 27.5%, 50%, 72.5%, and 95% percentiles. We then performed proportional hazards regression modeling with adjustment for the same covariates as in our primary analysis. We tested for nonlinearity using a likelihood ratio test. The relative hazards of subsequent ischemic stroke were graphed.

2. We created a logistic regression model incorporating all covariates within our primary analysis, and we created a propensity score to predict hyperglycemia versus normoglycemia. Using a caliper of 0.05, we matched hyperglycemic patients on a 1:1 ratio with a propensity-score matched patient without hyperglycemia and replicated our primary analysis restricted to this subgroup.

3. We replicated the main analysis substituting “acute infarction on an imaging study that was attributed to the index event” for “final diagnosis of index event based on symptoms, signs, and imaging data.”

4. We performed subgroup analyses restricted to (1) patients with minor stroke as the index event and (2) patients with TIA as the index event.

All hypothesis testing was 2-sided, and the threshold for statistical significance was set at α=0.05. We did not perform imputation for missing data. Statistical analyses were performed using R (version 4.03).

RESULTS
Patient Characteristics
Overall, 4878 patients were included in this analysis after 3 patients without recorded serum glucose values were excluded. The mean age of subjects in this analysis was 64.6±13.1 years, 45% were women, and 594 (12.2%) were hyperglycemic on presentation. Nine hundred sixty-six (19.8%) patients were Black
and 387 (7.9%) were Hispanic. Patients with hyperglycemia on presentation were more likely to be Hispanic (12.3% versus 7.3%, \( P<0.001 \)) and to have hypertension (83.5% versus 67.1%, \( P<0.001 \)), diabetes (85.7% versus 19.4%, \( P<0.001 \)), congestive cardiac failure (4.5% versus 2.3%, \( P=0.002 \)), coronary artery disease (13.1% versus 9.8%, \( P=0.01 \)), or an index event consistent with minor ischemic stroke (56.7% versus 45.9%, \( P<0.001 \)). Key demographic and clinical characteristics of the study population are presented in Table 1.

### Study End Points

During 90 days of follow-up, 267 out of 4878 patients had a subsequent ischemic stroke. The cumulative incidence of subsequent ischemic stroke was 9.7% (95% CI, 7.2%–12.2%) in patients with hyperglycemia and 5.2% (95% CI, 4.5%–5.8%) in normoglycemic patients (\( P<0.001 \) by the log-rank test) (Figure 1). The hazard of subsequent ischemic stroke was higher among patients with hyperglycemia than among normoglycemic patients (HR, 1.88 [95% CI, 1.39–2.53]; \( P<0.001 \)) in an unadjusted proportional hazards regression model (Table 2). In a fully adjusted model (including age, biological sex, race, ethnicity, treatment assignment, index event classification, and vascular risk factors as covariates), a significant association remained between admission hyperglycemia and subsequent ischemic stroke (HR, 1.5 [95% CI, 1.05–2.14]; \( P=0.01 \)). There was no significant association between hyperglycemia and major hemorrhage in a model adjusted for age, biological sex, race, ethnicity, treatment assignment, final adjudicated cause, and hypertension (HR, 0.47 [95% CI, 0.11–1.99]; \( P=0.31 \)). There was a significant association between hyperglycemia and the composite of ischemic stroke, myocardial infarction, or vascular death (HR, 1.55 [95% CI, 1.10–2.20]; \( P=0.01 \)).

### Interaction Analyses

In patients with hyperglycemia, treatment with dual antiplatelet therapy was not associated with a reduced

---

**Table 1. Demographics and Key Clinical Characteristics of Patients Included in This Study**

|                        | All, N=4878 | Hyperglycemia, n=594 | Normoglycemia, n=4284 | \( P \) value |
|------------------------|-------------|-----------------------|------------------------|---------------|
| **Demographics**       |             |                       |                        |               |
| Age, y, mean±SD        | 64.6±13.1   | 62.6±11.5             | 64.8±13.3              | <0.001        |
| Women                  | 2194 (45%)  | 248 (41.8%)           | 1946 (45.4%)           | 0.1           |
| Black*                 | 966 (19.8%) | 123 (20.7%)           | 843 (19.7%)            | 0.59          |
| Hispanic†              | 387 (7.9%)  | 73 (12.3%)            | 314 (7.3%)             | <0.001        |
| **Comorbidities**      |             |                       |                        |               |
| Hypertension‡          | 3371 (69.1%)| 496 (83.5%)           | 2875 (67.1%)           | <0.001        |
| Diabetes§              | 1340 (27.5%)| 120 (20.1%)           | 1220 (28.2%)           | <0.001        |
| Congestive cardiac failure¶| 126 (2.6%) | 78 (13.1%)            | 48 (1.1%)              | 0.002         |
| Atrial fibrillation¶   | 49 (1%)     | 4 (0.7%)              | 45 (1.1%)              | 0.52          |
| Coronary artery disease¶ | 497 (10.2%)| 78 (13.1%)           | 419 (9.8%)             | 0.01          |
| Valvular disease**     | 83 (1.7%)   | 8 (1.3%)              | 75 (1.8%)              | 0.59          |
| Carotid disease††      | 208 (4.3%)  | 31 (5.2%)             | 177 (4.1%)             | 0.26          |
| Active smoking‡‡       | 1003 (20.6%)| 109 (18.4%)           | 894 (20.9%)            | 0.17          |
| Index stroke§§         | 2304 (47.2%)| 337 (56.7%)           | 1967 (45.9%)           | <0.001        |
| Assigned to clopidogrel| 2430 (49.8%)| 307 (51.7%)           | 2123 (49.6%)           | 0.35          |
| Subsequent stroke      | 267 (5.5%)  | 54 (9.1%)             | 213 (5%)               | <0.001        |

*POINTER indicates Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke.
*Other racial groups represented in this sample included 3555 (72.9%) White patients, 144 (3%) Asian patients, 23 (0.5%) American Indian/Alaskan Native patients, 15 (0.3%) Native Hawaiian patients, 9 (0.2%) patients of >1 race, 26 (0.5%) patients labeled as “other,” and 140 (2.9%) patients who were “unknown/not reported.” Within the POIN study, the 140 “unknown” patients were not included in the denominator, hence the discrepancy between the percentages reported between that study and the present one.
†There were 230 patients labeled as being of unknown ethnicity.
‡There were 21 patients labeled as unknown hypertension status.
§There were 9 patients missing data on diabetes.
¶There were 7 patients labeled as unknown congestive cardiac failure status.
‖There were 4 patients labeled as unknown atrial fibrillation status.
‖‖There were 12 patients labeled as unknown coronary artery disease status.
‖§There were 12 patients labeled as unknown valvular disease status.
‖‖There were 32 patients labeled as unknown carotid disease status.
‖‖‖There were 4 patients missing data on smoking status.
‖‖‖‖There were 3 patients who had missing data on index event (minor stroke vs transient ischemic attack).
hazard of subsequent ischemic stroke in an unadjusted Cox model (HR, 1.18 [95% CI, 0.69–2.03]). In patients with normoglycemia, treatment with dual antiplatelet therapy was associated with a lower hazard of subsequent ischemic stroke (HR, 0.63 [95% CI, 0.48–0.83]). The P value for interaction was 0.04. We observed similar results for the composite end point of stroke, myocardial infarction, and vascular death (Table 3). The low number of major hemorrhages observed in this sample did not permit an interaction analysis. There was no significant interaction between hyperglycemia and final adjudicated cause (minor stroke versus TIA) on these end points (Table S1).

Sensitivity Analyses

Incorporating Serum Glucose as a Continuous Variable

There was evidence of a nonlinear relationship between serum glucose and subsequent stroke risk (P<0.001). Figure 2 assesses glucose as a restricted cubic spline rather than as a categorical variable. The restricted cubic spline for the risk of subsequent stroke was positively sloped with a gradual inflection in the 100 to 150 mg/dL range with a plateau at approximately 200 mg/dL.

Propensity Score–Matched Cohort

We compared the hazard of subsequent stroke between 554 (out of 594) patients with hyperglycemia and 554 propensity score–matched controls with normoglycemia. The association with subsequent stroke was not evident in this analysis (HR, 1.42 [95% CI, 0.92–2.12]). There was satisfactory matching of propensity scores across groups (Figure S1).

Alternative Definition of Index Event

Incorporating “acute infarction on an imaging study that was attributed to the index event” instead of final adjudicated cause, the association with subsequent stroke persisted (adjusted HR, 1.47 [95% CI, 1.03–2.11]; P=0.03).

Table 2. Association Between Hyperglycemia and Subsequent Ischemic Stroke

| Model | HR* (95% CI)   |
|-------|----------------|
| 1. Unadjusted | 1.87 (1.39–2.53) |
| 2. Model 1+age, biological sex, race, and ethnicity | 1.93 (1.43–2.61) |
| 3. Model 2+treatment assignment† and index event‡ | 1.77 (1.31–2.39) |
| 4. Model 3+vascular risk factors§ (excluding diabetes) | 1.71 (1.26–2.32) |
| 5. Model 4+vascular risk factors (including diabetes) | 1.5 (1.05–2.14) |

HR indicates hazard ratio.

†HR is for the comparison of hyperglycemia vs normoglycemia.

‡Treatment assignment includes aspirin/clopidogrel compared with aspirin/placebo (on intention-to-treat basis).

§Index event denotes minor ischemic stroke compared with high-risk transient ischemic attack/other diagnosis.

Vascular risk factors include hypertension, congestive cardiac failure, atrial fibrillation, coronary artery disease, valvular disease, carotid disease, and active smoking.
Mac Grory et al Hyperglycemia and Subsequent Stroke

Subgroup Analyses
In the 2327 patients whose index event was a TIA, there was a higher hazard of subsequent stroke in an unadjusted model (HR, 2.35 [95% CI, 1.28–4.31]) but a nonsignificant association in a fully adjusted model (HR, 1.67 [95% CI, 0.83–3.35]). In the 2304 patients whose index event was an acute minor ischemic stroke, there was a higher hazard of subsequent stroke in an unadjusted model (HR, 1.5 [95% CI, 1.05–2.15]) but not in a fully adjusted model (HR, 1.48 [95% CI, 0.95–2.29]).

DISCUSSION
We found that patients with hyperglycemia had a higher risk of subsequent ischemic stroke than patients with normoglycemia within the POINT clinical trial. The association between hyperglycemia and subsequent ischemic stroke persisted even after adjustment for demographics and clinical covariates that are known to predict subsequent stroke. The benefits of clopidogrel/aspirin were not apparent in the small subgroup of patients with hyperglycemia, with an interaction observed between clopidogrel and serum glucose on subsequent stroke.

There are several possible explanations for this association. First, hyperglycemia on presentation may be a marker of undiagnosed or poorly controlled diabetes, signifying a population known to be at high risk of subsequent stroke. Second, hyperglycemia may act as a surrogate for overall illness and thus a marker of an inflammatory prothrombotic state. Third, it increases the likelihood of developing infection, itself a risk factor.

Table 3. Association Between Treatment Assignment (Clopidogrel Versus Placebo) and Key Study End Points in Patients With and Without Hyperglycemia

| Outcome               | Aspirin/clopidogel, n=2430 | Aspirin/placebo, n=2448 | HR (95% CI)* | P value | P value for interaction |
|-----------------------|----------------------------|-------------------------|--------------|---------|-------------------------|
| Ischemic stroke       |                            |                         |              |         |                         |
| <180 mg/dL            | 82/2123                    | 131/2161                | 0.63 (0.48–0.83) | <0.001  | 0.04                    |
| ≥180 mg/dL            | 30/307                     | 24/287                  | 1.18 (0.84–0.203) | 0.50    |                         |
| Major hemorrhage      |                            |                         |              |         |                         |
| <180 mg/dL            | 21/2123                    | 10/2161                 | 2.14 (1.01–4.54) | 0.05    |                         |
| ≥180 mg/dL            | 2/307                      | 0/287                   | ...          | ...     |                         |
| Primary end point†    |                            |                         |              |         |                         |
| <180 mg/dL            | 89/2123                    | 134/2161                | 0.67 (0.51–0.87) | 0.003   | 0.06                    |
| ≥180 mg/dL            | 32/207                     | 26/287                  | 1.17 (0.70–1.96) | 0.55    |                         |

HRs are for the association between clopidogrel and the end point within the <180 mg/dL and ≥180 mg/dL strata. The interaction term is derived from a model including all patients in the study sample, which includes the term clopidogrel*hyperglycemia. HR indicates hazard ratio.

*Unadjusted HR.
†Subsequent ischemic stroke, myocardial infarction, ischemic vascular death.
for stroke\textsuperscript{21}; thus, hyperglycemia may act as an intermediate step in the development of subsequent stroke. Fourth, there may be a causal relationship between hyperglycemia and stroke. There are several mechanisms described linking transient short-term hyperglycemia with thrombus formation.\textsuperscript{22,23} In subjects with and without diabetes, there is a linear correlation between fasting serum glucose and coagulation factor VII.\textsuperscript{22} In healthy individuals, elevated thrombin–antithrombin complex and tissue factor are observed after only 3 hours of induced hyperglycemia and further accentuated by an induced inflammatory response.\textsuperscript{24} Transient hyperglycemia is typically followed by transient hyperinsulinemia in healthy subjects, and this combined elevation of serum glucose and insulin have been shown to have an additive effect on enhancing circulating tissue factor and other components of the coagulation system.\textsuperscript{25} Acute hyperglycemia also has deleterious effects on the vascular endothelium, and increased extracellular glucose increases the propensity to platelet activation and endothelial dysfunction.\textsuperscript{26–28} The mechanisms linking hyperglycemia to thrombus formation independent of platelet function may explain the apparent lack of effect of dual antiplatelet therapy in the subgroup of patients with hyperglycemia, although given the low number, this may also represent a type I error.

One previous study\textsuperscript{11} examined glycemic control as a predictor of subsequent stroke in the CHANCE (Clopidogrel in High-Risk Patients With Acute Nondisabling Events) trial.\textsuperscript{29} Using the glucose/glycosylated albumin ratio they found that patients in the highest quartile had an HR of 1.46 (95% CI, 1.06–2.01) of subsequent stroke compared with patients in the lowest quartile. This study was performed in an exclusively Chinese population and relied on 2 separate assays (serum glucose and glycosylated albumin), calculation of a ratio, then classification into quartiles. The current study overcomes the limitations inherent in this prior study by (1) focusing on 1 simple, rapid measurement of serum glucose, and (2) testing our hypothesis in a population more diverse and representative with respect to race, ethnicity, and national origin.

Currently, direct serum glucose measurements are not incorporated in stroke risk classification schemes. However, the presence/absence of diabetes is included in scores used to predict subsequent stroke after TIA\textsuperscript{9,10} and risk of stroke in atrial fibrillation.\textsuperscript{30} Subsequent stroke risk may be estimated based on imaging characteristics or cause classification.\textsuperscript{31} The ABCD\textsuperscript{2} and California\textsuperscript{10} scores aim to predict the risk of stroke after an index TIA at 7 and 90 days, respectively, by combining data on vascular risk factors and characteristics of the presenting stroke. However, there is a heightened risk of stroke within a short period of time after the index event,\textsuperscript{1} which suggests that more short-term, dynamic factors are likely at play. Serum glucose may be a useful measure for identifying patients at high-risk of early recurrence. By contrast, assay of glycosylated hemoglobin is reflective only of glycemic control over a period of approximately 2.5 months.\textsuperscript{32} Additionally, measurement of serum glucose can be performed rapidly, is inexpensive, and does not require calculation. For this reason, its use is proposed in 2 scoring systems for predicting hemorrhage after intravenous tissue plasminogen activator (IV tissue-type plasminogen activator) use (the TAG\textsuperscript{33} and SEDAN scores\textsuperscript{34}).

The SHINE trial\textsuperscript{14} randomized 1151 patients with hyperglycemia on presentation to either intensive therapy via continuous intravenous insulin infusion (target glucose 80–130 mg/dL) or standard therapy (target glucose 80–179 mg/dL) via an insulin sliding scale administered subcutaneously. There was no difference in the primary outcome (proportion of patients with a favorable score on the modified Rankin Scale at 90 days) between the 2 groups and more episodes of hypoglycemia in the intensive versus standard therapy groups (11.2% versus 3.2%). Subsequent ischemic stroke was not ascertained as a secondary outcome in this trial, but there were an equivalent number of ischaemic strokes (16) reported across each arm as a serious adverse event. Although not specifically designed to test the hypothesis that control of serum glucose reduced the risk of subsequent stroke, the results suggest that elevated serum glucose may be a marker of overall sickness/illness severity and not a target for therapy itself.

There are limitations inherent in this study. First, because this is a secondary analysis of data already collected from a well-phenotyped clinical trial population with high-risk TIA or acute minor ischemic stroke, our results should be used for hypothesis generation only. Second, the subgroup of patients with hyperglycemia was small (12.2% of the study sample), which limits our power to observe true effects. In particular, our finding that dual antiplatelet therapy was not associated with a reduced risk of subsequent stroke should be interpreted with caution and should not be evoked as a reason to deviate from guideline-based care in this population (the most recent American Heart Association stroke secondary prevention guidelines advocate for the use of dual antiplatelet therapy for 21 to 90 days for patients with noncardioembolic minor ischemic stroke or high-risk TIA\textsuperscript{35}). Third, the POINT excluded patients who received IV tissue-type plasminogen activator, underwent mechanical thrombectomy, had an indication for anticoagulation, or were planned for a revascularization procedure, and so our results may not apply to these groups of patients. Fourth, hypo- or hyperglycemia can cause acute, focal neurological deficits. Although abnormalities in serum
CONCLUSIONS
There was a higher rate of subsequent ischemic stroke and no clear benefit to dual antiplatelet therapy in patients with hyperglycemia on admission. This study may provide further support for developing innovative secondary prevention strategies in this high-risk patient population.

ARTICLE INFORMATION
Received July 12, 2021; accepted November 30, 2021.

Affiliations
Department of Neurology (B.M.G., M.W., Y.X., W.F.); and Division of Cardiology, Department of Medicine (J.P.P.), Duke University School of Medicine, Durham, NC; Duke Clinical Research Institute, Durham, NC (J.P.P., Y.X.); Department of Neurology, Warren Alpert Medical School of Brown University, Providence, RI (S.Y.); Department of Neurology & Stroke and Hertie Institute for Clinical Brain Research, Eberhard Karls University Tübingen, Tübingen, Germany (S.P.); Department of Neurology, Yale University School of Medicine, New Haven, CT (A.D.H.); Department of Neurology, NYU Grossman School of Medicine, New York, NY (S.K.R.); and Dean’s Office, Dell Medical School, The University of Texas at Austin, Austin, TX (S.C.J.).

Sources of Funding
None.

Disclosures
S.Y. previously received funding (paid to the Department of Neurology at the Warren Alpert Medical School of Brown University) from Medtronic for outcomes adjudication within a clinical study. A.D.H. is funded by the National Institute on Aging (R01AG062770, R01AG066672), has research funding from Daichi Sankyo and Janssen, and has received honoraria from Boehringer Ingelheim and Portola. S.C.J. reports receiving research support from Sanofi and AstraZeneca. W.F. is funded by the National Institute of Neurological Disorders and Stroke (U01/NS102353 and P2C HD086844-060) and MicroTransponder Inc. The remaining authors have no disclosures to report.

Supplemental Material
Data S1
Table S1
Figure S1

REFERENCES
1. Coull AJ, Lovett JK, Rothwell PM; Study OV. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ. 2004;328:326. doi: 10.1136/bmj.37991.635266.44
2. Yaghhi S, Dehkhamghani S, Faz E, Jayaraman M, Tanweer O, Grory BM, Henniger N, Lansberg MG, Albers GW, Havenon A. The effect of hyperglycemia on infarct growth after reperfusion: an analysis of the

defuse 3 trial. J Stroke Cerebrovasc Dis. 2021;30:105380. 10.1016/j.jstrokecerebrovasdis.2020.105380
3. Masur S, Cox M, Bhatt DL, Smith EE, Elroit G, Fanorac GC, Schwamm L. Association of acute and chronic hyperglycemia with acute ischemic stroke outcomes post-thrombolyis: findings from get with the guidelines-stroke. J Am Heart Assoc. 2015;4:e002193. doi: 10.1161/JAHA.115.002193
4. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke. 2001;32:2426–2432. doi: 10.1161/hs1001.096194
5. Bruno A, Biller J, Adams HP, Clarke WR, Woolson RF, Williams LS, Hansen MD. Acute blood glucose level and outcome from ischemic stroke. Trial of org 10172 in acute stroke treatment (TOAST) investigators. Neurology. 1999;52:280–284. doi: 10.1212/WNL.52.2.280
6. Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. BMJ. 1997;314:1303–1306. doi: 10.1136/bmj.314.7090.1303
7. Rinkel GA, Nguyen TT, Guglielmi V, Groot AE, Posthuma L, Roos BQ, Weitemeyer M, Majoie CB, Lycklama à Nijeholt GJ, Emmer BJ, van der Worp HB, et al. High admission glucose is associated with poor outcome after endovascular treatment for ischemic stroke. Stroke. 2020;51:3215–3223. doi: 10.1161/STROKEAHA.120.029944
8. Chamorro A, Brown S, Amaro S, Hill MD, Muir KW, Dippel DJW, van Zwam W, Butcher K, Ford GA, den Hertog HM, et al. Glucose modifies the effect of endovascular thrombectomy in patients with acute stroke. Stroke. 2019;50:690–696. doi: 10.1161/STROKEAHA.118.022369
9. Rothwell PM, Gifford MF, Flossmann O, Lovelock CE, Redgrave JN, Warlow CP, Mehta Z. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet. 2005;366:29–36. doi: 10.1016/S0140-6736(05)66702-5
10. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of tia. JAMA. 2000;284:2901–2906. doi: 10.1001/jama.284.22.2901
11. Pan Y, Cai X, Jing J, Meng X, Li H, Wang Y, Zhao X, Liu L, Wang D, Johnston SC, et al. Stress hyperglycemia and prognosis of minor ischemic stroke and transient ischemic attack: the Chance study (clopidogrel in high-risk patients with acute nondisabling cerebrovascular events). Stroke. 2017;48:3006–3011. doi: 10.1161/STROKEAHA.117.018081
12. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M. STROBE Initiative. Strengthening the reporting of observational studies in epidemiology (strobe): explanation and elaboration. PLoS Med. 2007;4:e297. doi: 10.1371/journal.pmed.0040297
13. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesh YL; Clinical Research Collaboration NuETTN, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk tia. N Engl J Med. 2018;379:215–225. doi: 10.1056/NEJMoa1800410
14. Johnston KC, Bruno A, Pauls Q, Hall CE, Barrett KM, Barsan W, Finsler A, Van de Bruinhorst K, Janis S, Durkalski-Mauldin VL. Intensive vs standard treatment of hyperglycemia and functional outcome in patients with acute ischemic stroke: the shine randomized clinical trial. JAMA. 2019;322:326–335. doi: 10.1001/jama.2019.9346
15. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50:e344–e418. doi: 10.1161/STR.0000000000000221
16. Kamel H, Zhang C, Kleindorfer DO, Levitan EB, Howard VJ, Howard G, Soliman EZ, Johnston SC. Association of black race with early recurrence after minor ischemic stroke or transient ischemic attack: secondary analysis of the point randomized clinical trial. JAMA Neurol. 2020;77:601–605. doi: 10.1001/jamaneurol.2020.0010
17. Morganstern LB, Smith MA, Sánchez BN, Brown DL, Zahuranec DB, Garcia N, Kerber KA, Skolarus LE, Meuer WR, Burke JP, et al. Persistent ischemic stroke disparities despite declining incidence in Mexican Americans. Ann Neurol. 2013;74:778–785. doi: 10.1002/ana.23972
18. Rosenbaum PR, Rubin DR. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55. doi: 10.1093/biomet/70.1.41

J Am Heart Assoc. 2022;10:e023223. DOI: 10.1161/JAHA.121.023223
19. Van den Bergh G. Dynamic neuroendocrine responses to critical illness. *Front Neuroendocrinol*. 2002;23:370–391. doi: 10.1016/S0091-3222(02)00007-7

20. Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital setting. *N Engl J Med*. 2006;355:1903–1911. doi: 10.1056/NEJMcp060094

21. Eikind MSV, Boehme AK, Smith CJ, Meisel A, Buckwalter MS. Infection as a stroke risk factor and determinant of outcome after stroke. *Stroke*. 2020;51:3156–3168. doi: 10.1161/STROKEAHA.120.030429

22. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Torrella R. Blood glucose may condition factor vii levels in diabetic and normal subjects. *Diabetologia*. 1988;31:889–891. doi: 10.1007/BF00265372

23. Rao AK, Chouhan V, Chen X, Sun L, Boden G. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. *Diabetes*. 1999;48:1156–1161. doi: 10.2337/diabetes.48.5.1156

24. Stegenga ME, van der Crabben SN, Blümer RM, Levi M, Meijers JC, Serlie MJ, Tanck MW, Sauerwein HP, van der Poll T. Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. *Blood*. 2008;112:82–89. doi: 10.1182/blood-2007-11-121723

25. Vaidyula VR, Rao AK, Mozoll M, Homko C, Cheung P, Boden G. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet cd40 ligand. *Diabetes*. 2006;55:202–208. doi: 10.2337 diabetes.55.01.06.db05-1026

26. Nieuwdorp M, van Haeften TW, Gouverneur MC, Mooij HL, van Lieshout MH, Levi M, Meijers JC, Hollerman F, Hoekstra JB, Vink H, et al. Loss of endothelial glycoalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. *Diabetes*. 2006;55:480–486. doi: 10.2337/diabetes.55.02.06.db05-1103

27. D’Onofrio N, Sardu C, Paolissio P, Minicucci F, Gragnano F, Ferraraccio F, Panarese I, Scisciola L, Mauro C, Rizzo MR, et al. Microrna-33 and sirt1 influence the coronary thrombus burden in hyperglycemic stemi patients. *J Cell Physiol*. 2020;235:1438–1452. doi: 10.1002/jcp.29064

28. Worthley MI, Holmes AS, Willoughby SR, Kucia AM, Heresztyn T, Stewart S, Chirkov YY, Zeitz CJ, Horowitz JD. The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediated by superoxide production, resolution with intensive insulin administration. *J Am Coll Cardiol*. 2007;49:304–310. doi: 10.1016/j.jacc.2006.08.053

29. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Li H, Meng X, Cui L, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. *N Engl J Med*. 2013;369:11–19. doi: 10.1056/NEJMoa1215340

30. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Rodford MJ. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. *JAMA*. 2001;285:2864–2870. doi: 10.1001/jama.285.22.2864

31. Amarenco P, Lavallée PC, Labreuche J, Albers GW, Bornstein NM, Canhão P, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, et al. One-year risk of stroke after transient ischemic attack or minor stroke. *N Engl J Med*. 2016;374:1533–1542. doi: 10.1056/NEJMoa1412981

32. Nathan DM, Singer DE, Huxthall K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. *N Engl J Med*. 1984;310:341–346. doi: 10.1056/NEJM198402093100602

33. Montalvo M, Mistry E, Chang AD, Yakhind A, Dakay K, Asher I, Kausah A, Mistry A, Chittle R, Cutting S, et al. Predicting symptomatic intracranial haemorrhage after mechanical thrombectomy: the TAG score. *J Neurol Neurosurg Psychiatry*. 2019;90:1370–1374. doi: 10.1136/jnnp-2019-321184

34. Strbian D, Engelster S, Michel P, Meroetoja A, Sekoranja L, Ailhaud FJ, Mustanoja S, Kuzmanovic I, Sairanen T, Forss N, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score. *Ann Neurol*. 2012;71:634–641. doi: 10.1002/ana.23546

35. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. *Stroke*. 2021;52:e364–e467. doi: 10.1161/STR.0000000000000375
| Item No | Item | Recommendation | Page |
|--------|------|----------------|------|
| Title and abstract | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract  
(b) Provide in the abstract an informative and balanced summary of what was done and what was found | 1 |
| | | | 2 |
| Introduction | 2 | Explain the scientific background and rationale for the investigation being reported | 3 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 3 |
| Methods | 4 | Present key elements of study design early in the paper | 4 |
| Study design | 4 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 4 |
| Setting | 5 | | 4 |
| Participants | 6 | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up  
(b) For matched studies, give matching criteria and number of exposed and unexposed | 4 |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 4 & 5 |
| Data sources/ measurement | 8 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 4 & 5 |
| Bias | 9 | Describe any efforts to address potential sources of bias | 4 |
| Study size | 10 | Explain how the study size was arrived at | 5 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 4 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding  
(b) Describe any methods used to examine subgroups and interactions  
(c) Explain how missing data were addressed  
(d) If applicable, explain how loss to follow-up was addressed  
(g) Describe any sensitivity analyses | 6 |
| Results | 13 | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed  
(b) Give reasons for non-participation at each stage  
(c) Consider use of a flow diagram | 8 |
| | | | N/A |
| Descriptive data | 14 | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders  
(b) Indicate number of participants with missing data for each variable of interest  
(c) Summarise follow-up time (eg, average and total amount) | 8 |
| | | | 20 |
| Outcome data | 15 | Report numbers of outcome events or summary measures over time | 8 & 9 |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted | 9 |
estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included

(b) Report category boundaries when continuous variables were categorized

(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

Other analyses

Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

**Discussion**

| Key results | Summarise key results with reference to study objectives | 11 |
| Limitations | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 13 & 14 |
| Interpretation | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 14 |
| Generalisability | Discuss the generalisability (external validity) of the study results | 14 |

**Other information**

| Funding | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 1 |

*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.
Data S1.

#R Script for Exploratory analysis of POINT, Mac Grory et al. 2021.

#CONTENTS:
#0. General points and power calculations
#1. Input, inspection and merging of data
#2. Variables of interest
#3. Cleaning up variables of interest
#4. Recharacterizing variables
#5. Descriptive statistics
#6. Inferential statistics
#7. Table 1 ***TABLE 1***
#8. Kaplan-Meier curves ***FIGURE 1***
#9. Cox proportional hazards modelling
#--A. Unadjusted modelling
#--B. Adjusted modelling ***TABLE 2***
#--C. Interaction analyses
#1. Subgroup Analyses
#--1. Minor stroke only - KM/UA/A
#--2. TIA only - KM/UA/A
#--2. DAPT only - KM/UA/A ***TABLE 3***
#--2. SAPT only - KM/UA/A
#11. Sensitivity Analyses
#--11.1. Glucose as continuous variable ***FIGURE 2***
#--11.2. Propensity score-matched analysis
#12. Final sensitivity analysis - infarct on imaging instead of adjudicated etiology

#0. General points

#Running lines 1-495 creates analysis dataset

#Packages:
library(powerSurvEpi)
library(haven)
library(dplyr)
library(doBy)
library(reshape)
library(table1)
library(survival)
library(survminer)
library(survMisc)
library(ggpubr)
library(ggplot2)
library(MatchIt)
library(ipw)
library(rms)
library(splines)
library(pROC)
library(coxphw)
library(Hmisc)
library('mgcv')
library(visreg)

# We did not "attach" data at any point to maintain clarity given the multiple datasets that were created in the course of the analysis.

# The POINT dataset is comprised of the following individual data files, stored as separate .SAS files:
# Form00 - Eligibility Form
# Form01 - Demographics
# Form02 - ABCD2 Score
# Form03 - Modified Rankin Scale
# Form04 - NIH Stroke Scale
# Form05 - Medical History
# Form06 - Prior Medications
# Form07 - Index TIA/Stroke Symptoms
# Form08 - Vital Signs
# Form10 - Randomization Form
# Form11 - Head CT/MRI Scan
# Form12 - Electrocardiogram
# Form13 - Carotid Imaging Results
# Form14 - Questionnaire for Verifying Stroke Free Status
# Form15 - Morisky Questionnaire
# Form16 - Study Drug Compliance
# Form17 - End of Study
# Form18 - Concomitant Medications
# Form19 - SAE/Clinical Outcome Reporting Form
# Form20 - Final Diagnosis
# Form22 - Ancillary Biomarker study
# Pointoutcomes - All endpoints from both intention to treat and per protocol analysis

# Power Calculations
powerCT.default0(0.10, 267, 1.5, alpha = 0.05)

powerCT.default0(0.10, 267, 2, alpha = 0.05)

powerCT.default0(0.10, 267, 2.5, alpha = 0.05)

powerCT.default0(0.15, 267, 1.5,
alpha = 0.05)

powerCT.default(0.15, 267, 2, alpha = 0.05)

powerCT.default(0.15, 267, 2.5, alpha = 0.05)

powerCT.default(0.25, 267, 1.5, alpha = 0.05)

powerCT.default(0.25, 267, 2, alpha = 0.05)

powerCT.default(0.25, 267, 2.5, alpha = 0.05)

#1. Input, inspection and merging of data
#We required variables stored in "Form00", "Form 01", "Form02", "Form05", "Form20", and "pointoutcomes" for this study.
#The datasets of interest were loaded in to R as follows:
#OFFICE
form00 <- read_sas("C:/Users/bcm39/Desktop/POINT Sub-study/POINT DATA/POINT Datasets/form00.sas7bdat", NULL)
form01 <- read_sas("C:/Users/bcm39/Desktop/POINT Sub-study/POINT DATA/POINT Datasets/form01.sas7bdat", NULL)
form02 <- read_sas("C:/Users/bcm39/Desktop/POINT Sub-study/POINT DATA/POINT Datasets/form02.sas7bdat", NULL)
form05 <- read_sas("C:/Users/bcm39/Desktop/POINT Sub-study/POINT DATA/POINT Datasets/form05.sas7bdat", NULL)
form20 <- read_sas("C:/Users/bcm39/Desktop/POINT Sub-study/POINT DATA/POINT Datasets/form20.sas7bdat", NULL)
pointoutcomes <- read_sas("C:/Users/bcm39/Desktop/POINT Sub-study/POINT DATA/POINT Datasets/pointoutcomes.sas7bdat", NULL)

#HOME
#form00 <- read_sas("POINT/POINT Datasets/form00.sas7bdat", NULL)
#form01 <- read_sas("POINT/POINT Datasets/form01.sas7bdat", NULL)
#form02 <- read_sas("POINT/POINT Datasets/form02.sas7bdat", NULL)
#form05 <- read_sas("POINT/POINT Datasets/form05.sas7bdat", NULL)
#form20 <- read_sas("POINT/POINT Datasets/form20.sas7bdat", NULL)
#pointoutcomes <- read_sas("POINT/POINT Datasets/pointoutcomes.sas7bdat", NULL)
# We visually inspected the data files before analysis
# View(form00)
# View(form01)
# View(form02)
# View(form05)
# View(form20)
# View(pointoutcomes)

# Then examined their structure
str(form00)
str(form01)
str(form02)
str(form05)
str(form20)
str(pointoutcomes)

# File merging
# Files were merged using "subject_id" as the linkage variable
merge1 <- left_join(form00, form01, by = "subject_id", copy = FALSE)
merge2 <- left_join(merge1, form02, by = "subject_id", copy = FALSE)
merge3 <- left_join(merge2, form05, by = "subject_id", copy = FALSE)
merge4 <- left_join(merge3, form20, by = "subject_id", copy = FALSE)
data <- left_join(merge4, pointoutcomes, by = "subject_id", copy = FALSE)

# For this project, there were 4,881 observation units or less in each data file and thus we did not need to rearrange from skinny to fat dataframes

# We manually inspected the new analysis data set
# View(data)

# 2. Variables of interest
data$age # Age (Form 00)
data$F00Q28 # Serum glucose (Form 00)
data$F00Q48 # Glucose units (Form 00)
data$GENDER # Gender (Form 01)
data$RACE # Race (Form 01)
data$ABCD2 # ABCD2 Score (Form 02)
data$F05Q01 # Congestive Heart Failure (Form 05)
data$F05Q02 # Atrial Fibrillation (Form 05)
data$F05Q03 # Ischemic Heart Disease (Form 05)
data$F05Q04 # Valvular Heart Disease (Form 05)
data$F05Q05 # Carotid stenosis/Endarterectomy/Stent/Angioplasty (Form 05)
data$F05Q06 # Hypertension (Form 05)
data$F05Q07 # Diabetes Mellitus (Form 05)
data$Smoke # Smoking status (Form 05)
data$F20Q01 # Final diagnosis of TIA (1) vs. Minor Stroke (2) (Form 20)
data$tx # Treatment assignment (from ITT analysis) - A: Placebo, B=Clopidogrel
data$itt_outcome_type4 # Subsequent ischemic stroke (pointoutcomes)
#3. Cleaning up variables of interest

# Age (Form 00)
# Manual inspection:
```r
data$age
summary(data$age)
sum(is.na(data$age)==FALSE)
sum(is.na(data$age)==TRUE)
# Age was initially stored as a factor.
table(data$age)
# There were also 73 patients with >89 listed as their age.
# For the purposes of this analysis we assigned the age 90 to them.
data$age[data$age==">89"] <- 90
table(data$age)
# We did this prior to conversion to a numeric variable to avoid introducing NAs
data$age <- as.numeric(data$age)
table(data$age)
summary(data$age)
hist(data$age)
sum(is.na(data$age)==FALSE)
sum(is.na(data$age)==TRUE)
```

# Serum glucose (Form 00)
```r
data$F00Q28
str(data$F00Q28)
# Glucose is already stored as a numeric variable
sum(is.na(data$F00Q28)==FALSE)
sum(is.na(data$F00Q28)==TRUE)
# 3 Subjects have missing information for this variable
# We will remove them from the analysis dataset
data[is.na(data$F00Q28),]
nrow(data)
data <- data[!is.na(data$F00Q28),]
nrow(data) # 3 subjects have been excluded from this analysis
summary(data$F00Q28)
hist(data$F00Q28)
# Around 500 people have implausibly low glucose readings from inspecting the histogram
table(data$F00Q48)
# 595 people have glucose stored in a different unit, explaining these apparently low readings
# From the data dictionary, serum glucose was stored in two units - mg/dl and mmol/L
# Before proceeding further with the analysis, we had to harmonize units
# Convert 2 (mmol/L) to 1 (mg/dL)
# Conversion factor = 18.0182
data$F00Q28[data$F00Q48 == 2] <- (data$F00Q28[data$F00Q48 == 2]*18.0182)
hist(data$F00Q28)
str(data$F00Q28)
```
sort(data$F00Q28, decreasing=FALSE)
data$glucose <- data$F00Q28

# There remains one person with an implausible low glucose reading of 7.8
# However, on the basis of the information contained in the dataset, I cannot definitively state this is not real
# If this was a mmol/L measurement, it would still be below the threshold of 180mg/dl
# So for the main analyses this subject will still be classed as "not hypoglycemic"
# We then created a dummy variable (entitled "hyperglycemia")
# We dichotomized patients in to >= 180 ("1") or <180 ("0")
data$hyperglycemia <- ifelse(data$glucose >=180, "1", "0")
str(data$hyperglycemia)
plot(data$hyperglycemia, data$glucose)
sum(is.na(data$hyperglycemia))

# Gender (Form 01)
data$GENDER
str(data$GENDER)
sum(is.na(data$GENDER)==TRUE)
data$GENDER <- as.factor(data$GENDER)
str(data$GENDER)
table(data$GENDER)
data$female <- data$GENDER
table(data$female)

# Ethnicity (Form 01)
# 0 - Hispanic/Latino; 1 - Not hispanic or latino; 3 - Unknown
# We altered this to a dichotomous variable where subjects are classed as 1 (Hispanic/Latino) or 2(Not hispanic/latino)
data$ETHNIC
sum(is.na(data$ETHNIC)==FALSE)
sum(is.na(data$ETHNIC)==TRUE)
table(data$ETHNIC)
data$ETHNIC[data$ETHNIC==3] <- "1"
data$ETHNIC[data$ETHNIC==1] <- "2"
data$ETHNIC[data$ETHNIC==0] <- "1"
data$ETHNIC[data$ETHNIC==2] <- "0"
table(data$ETHNIC)
str(data$ETHNIC)
data$hispanic <- data$ETHNIC
data$hispanic <- as.factor(data$hispanic)
table(data$hispanic)
str(data$hispanic)

# Race (Form 01)
# 0 - American Indian/Alaskan Native, 1 - Asian, 2 - Black/African American, 3 - Native Hawaiian, 4 - White, 5 - More than one race, 98 - Other, 99 - Unknown/not reported
str(data$RACE)
table(data$RACE)
sum(is.na(data$ETHNIC)==FALSE)
sum(is.na(data$ETHNIC)==TRUE)
# We altered this to a dichotomous variable where subjects are classed as "Black" or "Non-Black"
data$RACE[data$RACE==1] <- "0"
data$RACE[data$RACE==3] <- "0"
data$RACE[data$RACE==4] <- "0"
data$RACE[data$RACE==5] <- "0"
data$RACE[data$RACE==98] <- "0"
data$RACE[data$RACE==99] <- "0"
data$RACE[data$RACE==2] <- "1"
data$black <- data$RACE
str(data$black)
data$black <- as.factor(data$black)
str(data$black)
table(data$black)

#ABCD2 Score (Form 02)
data$ABCD2
str(data$ABCD2)
table(data$ABCD2)
sum(is.na(data$ABCD2[data$F20Q01==2]))
#1594 missing
sum(is.na(data$ABCD2[data$F20Q01==98]))
#132 missing
sum(is.na(data$ABCD2[data$F20Q01==1]))
#422 missing
#Very high volume of missing data in this variable, even among patients whose final adjudicated etiology was TIA so we chose to exclude it.

#Congestive Heart Failure (Form 05)
data$F05Q01
sum(is.na(data$F05Q01)==FALSE)
sum(is.na(data$F05Q01)==TRUE)
table(data$F05Q01)
#7 patients had "Unknown" CHF status
str(data$F05Q01)
data$F05Q01[data$F05Q01==2] <- "0"
table(data$F05Q01)
str(data$F05Q01)
data$chf <- data$F05Q01
str(data$chf)

#Atrial Fibrillation (Form 05)
data$F05Q02
sum(is.na(data$F05Q02)==FALSE)
sum(is.na(data$F05Q02)==TRUE)
table(data$F05Q02)
#14 patients had "Unknown" AF status
str(data$F05Q02)
data$F05Q02[data$F05Q02==2] <- "0"
table(data$F05Q02)
str(data$F05Q02)
data$F05Q02 <- as.factor(data$F05Q02)
str(data$F05Q02)
data$af <- data$F05Q02
str(data$af)

#Ischemic Heart Disease (Form 05)
data$F05Q03
sum(is.na(data$F05Q03)==FALSE)
sum(is.na(data$F05Q03)==TRUE)
table(data$F05Q03)
#12 patients had "Unknown" CHF status
str(data$F05Q03)
data$F05Q03[data$F05Q03==2] <- "0"
table(data$F05Q03)
str(data$F05Q03)
data$F05Q03 <- as.factor(data$F05Q03)
str(data$F05Q03)
data$cad <- data$F05Q03
str(data$cad)

#Valvular Heart Disease (Form 05)
data$F05Q04
sum(is.na(data$F05Q04)==FALSE)
sum(is.na(data$F05Q04)==TRUE)
table(data$F05Q04)
#12 patients had "Unknown" Valvular heart disease status
str(data$F05Q04)
data$F05Q04[data$F05Q04==2] <- "0"
table(data$F05Q04)
str(data$F05Q04)
data$F05Q04 <- as.factor(data$F05Q04)
str(data$F05Q04)
data$valvedisease <- data$F05Q04
str(data$valvedisease)

#Carotid stenosis/Endarterectomy/Stent/Angioplasty (Form 05)
data$F05Q05
sum(is.na(data$F05Q05)==FALSE)
sum(is.na(data$F05Q05)==TRUE)
table(data$F05Q05)
#32 patients had "Unknown" carotid stenosis/endarterectomy/stent/angioplasty
str(data$F05Q05)
data$F05Q05[data$F05Q05==2] <- "0"
table(data$F05Q05)
str(data$F05Q05)
data$F05Q05 <- as.factor(data$F05Q05)
str(data$F05Q05)
data$carotiddisease <- data$F05Q05
str(data$carotiddisease)

#Hypertension (Form 05)
data$F05Q06
sum(is.na(data$F05Q06)==FALSE)
sum(is.na(data$F05Q06)==TRUE)
table(data$F05Q06)
#21 patients were "Unknown" hypertension status
str(data$F05Q06)
data$F05Q06[data$F05Q06==2] <- "0"
table(data$F05Q06)
str(data$F05Q06)
data$F05Q06 <- as.factor(data$F05Q06)
str(data$F05Q06)
data$htn <- data$F05Q06
str(data$htn)

#Diabetes Mellitus (Form 05)
data$F05Q07
sum(is.na(data$F05Q07)==FALSE)
sum(is.na(data$F05Q07)==TRUE)
table(data$F05Q07)
#9 patients were "Unknown" diabetes mellitus status
str(data$F05Q07)
data$F05Q07[data$F05Q07==2] <- "0"
table(data$F05Q07)
str(data$F05Q07)
data$F05Q07 <- as.factor(data$F05Q07)
str(data$F05Q07)
data$diabetes <- data$F05Q07
str(data$diabetes)

#Smoking status (Form 05)
data$smoke
str(data$smoke)
sum(is.na(data$smoke)==FALSE)
sum(is.na(data$smoke)==TRUE)
#4 patients had missing data on smoking
table(data$smoke)
#We considered active smoking as smoking (1) and past/never smoking as not smoking (0)
data$smoke[data$smoke==1] <- "0"
data$smoke[data$smoke==2] <- "1"
table(data$smoke)
str(data$smoke)
#The 4 patients had missing data on smoking were classified as "not smoking"
data$smoke[is.na(data$smoke)] <- "0"
data$smoke <- as.factor(data$smoke)
sum(is.na(data$smoke)==TRUE)
str(data$smoke)
data$smoking <- data$smoke
str(data$smoking)

#Final diagnosis of TIA (1) vs. Minor Stroke (2) (Form 20)
data$F20Q01
sum(is.na(data$F20Q01)==FALSE)
sum(is.na(data$F20Q01)==TRUE)
#3 patients had missing data
table(data$F20Q01)
str(data$F20Q01)
data$F20Q01[data$F20Q01==1] <- "0"
data$F20Q01[data$F20Q01==98] <- "0"
data$F20Q01[data$F20Q01==2] <- "1"
sum(is.na(data$F20Q01)==TRUE)
data$F20Q01[is.na(data$F20Q01)] <- 0
data$F20Q01 <- as.factor(data$F20Q01)
data$minorstroke <- data$F20Q01
table(data$minorstroke)
str(data$minorstroke)

#Treatment assignment (from ITT analysis) - A: Placebo, B=Clopidogrel
table(data$tx)
str(data$tx)
sum(is.na(data$tx)==FALSE)
sum(is.na(data$tx)==TRUE)
#No missing data on treatment assignment
data$tx[data$tx=="B"] <- "1"
data$tx[data$tx=="A"] <- "0"
table(data$tx)
str(data$tx)
data$tx <- as.factor(data$tx)
table(data$tx)
str(data$tx)
data$dapt <- data$tx
str(data$dapt)

#Subsequent ischemic stroke (pointoutcomes)
data$itt_outcome_type4
sum(is.na(data$itt_outcome_type4)==FALSE)
sum(is.na(data$itt_outcome_type4)==TRUE)
#No missing data on subsequent ischemic stroke
table(data$itt_outcome_type4)
str(data$itt_outcome_type4)
data$itt_outcome_type4 <- as.factor(data$itt_outcome_type4)
table(data$itt_outcome_type4)
str(data$itt_outcome_type4)
data$stroke <- data$itt_outcome_type4
str(data$stroke)
# Days from randomization to event (pointoutcomes)

data$sitt_outcome_type4_days

str(data$sitt_outcome_type4_days)

sum(is.na(data$sitt_outcome_type4_days) == FALSE)

sum(is.na(data$sitt_outcome_type4_days) == TRUE)

# No missing data on time to subsequent ischemic stroke

#table(data$sitt_outcome_type4_days)

data$sitt_outcome_type4_days <- as.numeric(data$sitt_outcome_type4_days)

str(data$sitt_outcome_type4_days)

data$days <- data$sitt_outcome_type4_days

str(data$days)

# 4. Recharacterizing variables

data$age # Age (Form 00) --> NUMERIC

data$glucose # Serum glucose (Form 00) --> NUMERIC

data$hyperglycemia # Hyperglycemia (dummy variable) --> CHARACTER

data$female # Female sex (Form 00) --> FACTOR

data$black # Race (Form 01) --> FACTOR

data$hispanic # ETHNIC (Form 01) --> FACTOR

data$chf # Congestive Heart Failure (Form 05) --> FACTOR

data$af # Atrial Fibrillation (Form 05) --> FACTOR

data$cad # Ischemic Heart Disease (Form 05) --> FACTOR

data$valvedisease # Valvular Heart Disease (Form 05) --> FACTOR

data$carotiddisease # Carotid stenosis/Endarterectomy/Stent/Angioplasty (Form 05) --> FACTOR

data$htn # Hypertension (Form 05) --> FACTOR

data$diabetes # Diabetes Mellitus (Form 05) --> FACTOR

data$smoking # Smoking status (Form 05) --> FACTOR

data$minorstroke # Final diagnosis of TIA (1) vs. Minor Stroke (2) (Form 20) --> FACTOR

data$dapt # Treatment assignment (from ITT analysis) - A: Placebo, B=Clopidogrel --> FACTOR

data$stroke # Subsequent ischemic stroke (pointoutcomes) --> FACTOR

data$days # Days from randomization to event (pointoutcomes) --> NUMERIC

#data$age <- as.numeric(data$age)

#data$GENDER <- as.factor(data$GENDER)

#data$F05Q01 <- as.numeric(data$F05Q02)

#data$F05Q02 <- as.numeric(data$F05Q02)

#data$F05Q03 <- as.numeric(data$F05Q03)

#data$F05Q06 <- as.numeric(data$F05Q06)

#data$smoke <- as.numeric(data$smoke)

#data$sitt_outcome_type4_days <- as.numeric(data$sitt_outcome_type4_days)

#data$sitt_outcome_type4 <- as.numeric(data$sitt_outcome_type4)

# 5. Descriptive statistics

# Age

summary(data$age[ data$hyperglycemia == 1 ],)
summary(data$age [data$hyperglycemia == 0],)
mean(data$age, na.rm=TRUE)
sd(data$age, na.rm=TRUE)

#Sex
table(data$female)
table(data$female [data$hyperglycemia == 1])
table(data$female [data$hyperglycemia == 0])

#Race
table(data$black)
table(data$black [data$hyperglycemia == 1])
table(data$black [data$hyperglycemia == 0])

#Ethnicity
table(data$hispanic)
table(data$hispanic [data$hyperglycemia == 1])
table(data$hispanic [data$hyperglycemia == 0])

#Hypertension
table(data$htn)
table(data$htn [data$hyperglycemia == 1])
table(data$htn [data$hyperglycemia == 0])

#Diabetes mellitus
table(data$diabetes)
table(data$diabetes [data$hyperglycemia == 1])
table(data$diabetes [data$hyperglycemia == 0])

#Atrial fibrillation
table(data$af)
table(data$af [data$hyperglycemia == 1])
table(data$af [data$hyperglycemia == 0])

#CAD
table(data$cad)
table(data$cad [data$hyperglycemia == 1])
table(data$cad [data$hyperglycemia == 0])

#CHF
table(data$chf)
table(data$chf [data$hyperglycemia == 1])
table(data$chf [data$hyperglycemia == 0])

#Tobacco use
table(data$smoking)
table(data$smoking [data$hyperglycemia == 1])
table(data$smoking [data$hyperglycemia == 0])

#Index stroke
table(data$minorstroke)
table(data$minorstroke [data$hyperglycemia == 1])
table(data$minorstroke [data$hyperglycemia == 0])

#Treatment assignment
table(data$dapt)
table(data$dapt [data$hyperglycemia == 1])
table(data$dapt [data$hyperglycemia == 0])
#6. Creating table 1

table.data <- data
	able.data$female <- factor(table.data$female, labels = c("Male","Female"))
table.data$black <- factor(table.data$black, labels = c("Non-Black","Black"))
table.data$hispanic <- factor(table.data$hispanic, labels = c("Non-Hispanic","Hispanic"))
table.data$hyperglycemia <- factor(table.data$hyperglycemia, labels = c("Normoglycemic","Hyperglycemic"))

label(table.data$age) <- "Age"
label(table.data$female) <- "Sex"
label(table.data$black) <- "Race"
label(table.data$hispanic) <- "Ethnicity"
label(table.data$htn) <- "Hypertension"
label(table.data$diabetes) <- "Diabetes Mellitus"
label(table.data$chf) <- "Congestive Heart Failure"
label(table.data$af) <- "Atrial Fibrillation"
label(table.data$cad) <- "Coronary Artery Disease"
label(table.data$valvedisease) <- "Valve Disease"
label(table.data$carotiddisease) <- "Carotid Disease"
label(table.data$smoking) <- "Smoking (active)"
label(table.data$minorstroke) <- "Minor Stroke"
label(table.data$dapt) <- "Dual Anti-platelet Therapy"
label(table.data$stroke) <- "Subsequent Stroke"
label(table.data$hyperglycemia) <- "Hyperglycemia"

# Creating table 1, comparing characteristics between the two groups

table1(~ table.data$age + table.data$female + table.data$black + table.data$hispanic + table.data$htn +
    table.data$diabetes +
    table.data$chf + table.data$af + table.data$cad + table.data$valvedisease +
    table.data$carotiddisease + table.data$smoking + table.data$minorstroke +
    table.data$dapt + table.data$stroke | table.data$hyperglycemia, data=table.data,
    topclass="Rtable1-grid Rtable1-shade Rtable1-times")

#7. Inferential statistics

#A. Comparing continuous variables with a t-test

hist(data$age[data$hyperglycemia==0])
hist(data$age[data$hyperglycemia==1])
t.test(data$age~data$hyperglycemia, data=data, var.equal=TRUE, conf.level=0.95)

#7B. Comparing categorical variables with a Chi Squared test

x <- table(data$female, data$hyperglycemia)
chisq.test(x)
x <- table(data$black, data$hyperglycemia)
chisq.test(x)
x <- table(data$hispanic, data$hyperglycemia)
chisq.test(x)
x <- table(data$htn, data$hyperglycemia)
chisq.test(x)
x <- table(data$diabetes, data$hyperglycemia)
chisq.test(x)
x <- table(data$chf, data$hyperglycemia)
chisq.test(x)
x <- table(data$af, data$hyperglycemia)
chisq.test(x)
x <- table(data$cad, data$hyperglycemia)
chisq.test(x)
x <- table(data$valvedisease, data$hyperglycemia)
chisq.test(x)
x <- table(data$carotiddisease, data$hyperglycemia)
chisq.test(x)
x <- table(data$smoking, data$hyperglycemia)
chisq.test(x)
x <- table(data$minorstroke, data$hyperglycemia)
chisq.test(x)
x <- table(data$dapt, data$hyperglycemia)
chisq.test(x)
x <- table(data$stroke, data$hyperglycemia)
chisq.test(x)

#8. Kaplan-Meier curves for Main Analysis

time <- data$days
event <- data$stroke
event <- as.numeric(event)

#Changing property of hyperglycemia variable as a way of troubleshooting
data$hyperglycemia <- as.numeric(data$hyperglycemia)
group <- data$hyperglycemia

summary(time)
summary(event)
summary(group)
kmsurvival <- survfit(Surv(time,event) ~ 1, conf.type="none")

summary (kmsurvival)

#Getting estimates with 95% CIs for each group at 90 days
kmsurvivalestimate <- survfit(Surv(time,event) ~ 1)

summary (kmsurvivalestimate, times=90)

#Estimate
1-0.943
#Upper CI
1-0.936
#Lower CI
1-0.95

#Getting estimates with 95% CIs for hyperglycemia group
hyperglycemicgroup <- data[data$hyperglycemia ==1,]
time <- hyperglycemicgroup$days
event <- hyperglycemicgroup$stroke
event <- as.numeric(event)
kmsurvival <- survfit(Surv(time,event) ~ 1, conf.type="none")
summary (kmsurvival)
kmsurvivalestimate <- survfit(Surv(time, event) ~ 1)
summary (kmsurvivalestimate, times=90)

# Estimate
1-0.903
# Upper CI
1-0.878
# Lower CI
1-0.928

# Getting estimates with 95% CIs for normoglycemia group
normoglycemicgroup <- data[data$hyperglycemia == 0,]
time <- normoglycemicgroup$days
event <- as.numeric(normoglycemicgroup$stroke)
event <- as.numeric(event)
kmsurvival <- survfit(Surv(time, event) ~ 1)
summary (kmsurvival)
plot(kmsurvival)

kmsurvivalestimate <- survfit(Surv(time, event) ~ 1)
summary (kmsurvivalestimate, times=90)

# Estimate
1-0.948
# Upper CI
1-0.942
# Lower CI
1-0.955

# Getting estimates with 95% CIs for normoglycemia group

# Curve for all patients in database
plot(kmsurvival)

# Curve stratified based on serum glucose (hyperglycemic or normoglycemic)
kmsurvival <- survfit(Surv(time, event) ~ group)
summary (kmsurvival)
plot(kmsurvival, fun="event", conf.type = "log")

# Comparing curves using the log Rank test
time <- data$days
event <- as.numeric(data$stroke)
event <- as.numeric(event)

# Changing property of hyperglycemia variable as a way of troubleshooting
data$hyperglycemia <- as.numeric(data$hyperglycemia)
group <- data$hyperglycemia
survdiff(Surv(time, event) ~ group + data$diabetes, data=data)
NB event has to be numeric and not a factor

We then created an annotated and labelled figure with two components

A. A large, labelled graph

```r
plot(kmsurvival, fun="event", xlab="Days Since Randomization", ylab="Proportion of Patients With Subsequent Stroke", lwd=1, ylim=c(0,1), col=c("red","blue"))
box (lwd=2)
axis(side=1, at = c(0,10,20,30,40,50,60,70,80,90))
axis(side=2, at = c(0,0.1,0.2,0.3,0.4,0.5,0.6,0.7,0.8,0.9,1))
legend("bottomright", c("Normoglycemia (<180mg/dl)", "Hyperglycemia (>180mg/dl)"), col=c("red", "blue"), lty=1)
```

B. A small insert with less conspicuous labelling and a smaller y access to magnify the area of interest

```r
plot(kmsurvival, fun="event", col=c("red","blue"))
legend("bottomright", c("Normoglycemia (<180mg/dl)", "Hyperglycemia (>180mg/dl)"), col=c("red", "blue"), lty=1)
```

We went on to do further manipulation of both graphs as follows:

Large Graph

```r
plot(kmsurvival, fun="event", col=c("red","red", "blue", "blue"), lwd=1, lty=c(1,5,1,5), ylim = c(0,1))
box(lwd=2)
axis(side=1, at = c(0,10,20,30,40,50,60,70,80,90))
axis(side=2, at = c(0,0.1,0.2,0.3,0.4,0.5,0.6,0.7,0.8,0.9,1))
legend("bottomright", c("Normoglycemia (<180mg/dl)", "Hyperglycemia (>180mg/dl)"), col=c("red", "blue"), lty=1)
```

Insert

```r
plot(kmsurvival, fun="event", col=c("red", "blue"), lwd=2, ylim = c(0,0.14), axes = TRUE)
box(lwd=2)
axis(side=1, at = c(0,30,60,90))
axis(side=2, at = c(0,0.01,0.02,0.03,0.04,0.05,0.06,0.07,0.08,0.09,0.1,0.11,0.12,0.13))
slegend("bottomright", c("Normoglycemia (<180mg/dl)", "Hyperglycemia (>180mg/dl)"), col=c("red", "blue"), lty=1)
```

9. Cox proportional hazards modeling

A. Unadjusted Cox Model

```r
time <- data$days
event <- data$stroke
group <- data$hyperglycemia
summary(time)
summary(event)
summary(group)
event <- as.numeric(event)
coxph <- coxph(Surv(time,event) ~ group, data=data, method="breslow")
summary(coxph)
```

B. Adjusted Cox Model

**MODEL 1 - unadjusted**

```r
coxph <- coxph(Surv(time,event) ~ data$hyperglycemia, method="breslow")
summary(coxph)
```

**MODEL 2 - Model 1 + Age, sex, race, ethnicity**

```r
coxph <- coxph(Surv(time,event) ~ data$hyperglycemia + data$age + data$female, method="breslow")
summary(coxph)
```
```r
summary(coxph)
coxph <- coxph(Surv(time, event) ~ data$hyperglycemia + data$age + data$female + data$black, method="breslow")
summary(coxph)
coxph <- coxph(Surv(time, event) ~ data$hyperglycemia + data$age + data$female + data$black + data$hispanic, method="breslow")
summary(coxph)

#MODEL 3 - Model 2 + treatment assignment and index event
coxph <- coxph(Surv(time, event) ~ data$hyperglycemia + data$age + data$female + data$black + data$hispanic + data$dapt + data$minorstroke, method="breslow")
summary(coxph)

#MODEL 4 - Model 3 + vascular risk factors (excluding diabetes mellitus)
coxph <- coxph(Surv(time, event) ~ data$hyperglycemia + data$age + data$female + data$black + data$hispanic + data$dapt + data$minorstroke + data$htn + data$chf + data$af + data$cad + data$valvedisease + data$carotiddisease + data$smoking, method="breslow")
summary(coxph)

#MODEL 5 - Model 4 + vascular risk factors (including diabetes mellitus)
coxph <- coxph(Surv(time, event) ~ data$hyperglycemia + data$age + data$female + data$black + data$hispanic + data$dapt + data$minorstroke + data$htn + data$chf + data$af + data$cad + data$valvedisease + data$carotiddisease + data$smoking + data$diabetes, method="breslow")
summary(coxph)

#MODEL 5 with major hemorrhage as outcome
#Major hemorrhage is itt_outcome_type11 in point outcomes
#Time to major hemorrhage is itt_outcome_type11_days in point outcomes
time <- data$itt_outcome_type11_days
event <- data$itt_outcome_type11
group <- data$hyperglycemia
summary(time)
summary(event)
summary(group)
event <- as.numeric(event)
coxph <- coxph(Surv(time, event) ~ data$hyperglycemia + data$age + data$female + data$black + data$hispanic + data$dapt + data$minorstroke + data$htn, method="breslow")
summary(coxph)

#MODEL 5 with composite as outcome
#Composite is itt_outcome_type1 in point outcomes
#Time to composite is itt_outcome_type1_days in point outcomes
time <- data$itt_outcome_type1_days
event <- data$itt_outcome_type1
group <- data$hyperglycemia
summary(time)
summary(event)
summary(group)
event <- as.numeric(event)
coxph <- coxph(Surv(time, event) ~ data$hyperglycemia + data$age + data$female + data$black + data$hispanic + data$dapt + data$minorstroke + data$htn, method="breslow")
summary(coxph)
```

coxph <- coxph(Surv(time,event) ~ data$hyperglycemia + data$age + data$female + data$black + data$hispanic +
data$dapt + data$minorstroke + data$htn + data$chf + data$af + data$cad + data$valvedisease + data$carotiddisease +
data$smoking + data$diabetes, method="breslow")
summary(coxph)

#C. Interaction Analyses
hyperglycemicgroup <- data[data$hyperglycemia ==1,]
normoglycemicgroup <- data[data$hyperglycemia ==0,]

#1---> Hyperglycemia and DAPT

#OUTCOME 1 - subsequent stroke

#Outcome 1 - major hemorrhage

#Major hemorrhage is itt_outcome_type11 in point outcomes
#Time to major hemorrhage is itt_outcome_type11_days in point outcomes

table(hyperglycemicgroup$itt_outcome_type11, hyperglycemicgroup$dapt)
table(normoglycemicgroup$itt_outcome_type11, normoglycemicgroup$dapt)

coxph <- coxph(Surv(time,event) ~ data$hyperglycemia, data=data, method="breslow")
summary(coxph)
coxph <- coxph(Surv(time,event) ~ data$dapt, data=data, method="breslow")
summary(coxph)
coxph <- coxph(Surv(time,event) ~ data$hyperglycemia + data$dapt, data=data, method="breslow")
summary(coxph)
coxph <- coxph(Surv(time,event) ~ data$hyperglycemia + data$dapt + data$hyperglycemia*data$dapt, data=data,
method="breslow")
summary(coxph)

#Outcome 2 - major hemorrhage

#Major hemorrhage is itt_outcome_type11 in point outcomes
#Time to major hemorrhage is itt_outcome_type11_days in point outcomes

In whole sample

time <- data$itt_outcome_type11_days
event <- data$itt_outcome_type11
group <- data$hyperglycemia
event <- as.numeric(event)
coxph <- coxph(Surv(time,event) ~ data$hyperglycemia, data=data, method="breslow")
summary(coxph)
coxph <- coxph(Surv(time,event) ~ data$dapt, data=data, method="breslow")
summary(coxph)
coxph <- coxph(Surv(time,event) ~ data$hyperglycemia + data$dapt, data=data, method="breslow")
summary(coxph)
coxph <- coxph(Surv(time,event) ~ data$hyperglycemia + data$dapt + data$hyperglycemia*data$dapt, data=data,
method="breslow")
summary(coxph)

#In hyperglycemic group - Major hemorrhage/DAPT

time <- hyperglycemicgroup$itt_outcome_type11_days
event <- hyperglycemicgroup$itt_outcome_type11
group <- data$dapt
event <- as.numeric(event)
coxph <- coxph(Surv(time,event) ~ hyperglycemicgroup$dapt, data=hyperglycemicgroup, method="breslow")
summary(coxph)

#Won't work as 0 events in SAPT group
# In normoglycemic group - Major hemorrhage/DAPT

```r
library(Survival)

time <- normoglycemicgroup$itt_outcome_type1_days
event <- normoglycemicgroup$itt_outcome_type1
group <- data$dapt
event <- as.numeric(event)
coxph <- coxph(Surv(time,event) ~ normoglycemicgroup$dapt, data=normoglycemicgroup, method="breslow")
summary(coxph)
```

# Outcome 3 - subsequent ischemic stroke, myocardial infarction or vascular death

# Composite is itt_outcome_type1 in point outcomes

# Time to composite is itt_outcome_type1_days in point outcomes

```r
table(hyperglycemicgroup$itt_outcome_type1, hyperglycemicgroup$dapt)
table(normoglycemicgroup$itt_outcome_type1, normoglycemicgroup$dapt)
```

# In whole sample

```r
time <- data$itt_outcome_type1_days
event <- data$itt_outcome_type1
group <- data$hyperglycemia
event <- as.numeric(event)
coxph <- coxph(Surv(time,event) ~ data$hyperglycemia, data=data, method="breslow")
summary(coxph)
coxph <- coxph(Surv(time,event) ~ group, data=data, method="breslow")
summary(coxph)
coxph <- coxph(Surv(time,event) ~ data$hyperglycemia + data$dapt, data=data, method="breslow")
summary(coxph)
coxph <- coxph(Surv(time,event) ~ data$hyperglycemia + data$dapt + data$hyperglycemia*data$dapt, data=data, method="breslow")
summary(coxph)
```

# In hyperglycemic group

```r
time <- hyperglycemicgroup$itt_outcome_type1_days
event <- hyperglycemicgroup$itt_outcome_type1
group <- hyperglycemicgroup$dapt
event <- as.numeric(event)
coxph <- coxph(Surv(time,event) ~ hyperglycemicgroup$dapt, data=hyperglycemicgroup, method="breslow")
summary(coxph)
```

# In normoglycemic group

```r
time <- normoglycemicgroup$itt_outcome_type1_days
event <- normoglycemicgroup$itt_outcome_type1
group <- normoglycemicgroup$dapt
event <- as.numeric(event)
coxph <- coxph(Surv(time,event) ~ normoglycemicgroup$dapt, data=normoglycemicgroup, method="breslow")
summary(coxph)
```

#2 --> Hyperglycemia and Stroke/TIA

```r
hyperglycemicgroup <- data[data$hyperglycemia ==1,]
normoglycemicgroup <- data[data$hyperglycemia ==0,]
minorstroke <- data[data$minorstroke ==1,]
tiaother <- data[data$minorstroke ==0,]
```
# Hyperglycemia and Stroke/TIA interaction analysis

# OUTCOME 1 - subsequent stroke

```r
table(minorstroke$stroke, minorstroke$hyperglycemia)
table(tiaother$stroke, tiaother$hyperglycemia)
```

# Whole sample

```r
time <- data$days
event <- data$stroke
group <- data$hyperglycemia
summary(time)
summary(event)
summary(group)
event <- as.numeric(event)
```

# Unadjusted main analysis

```r
coxph <- coxph(Surv(time,event) ~ data$hyperglycemia, data=data, method="breslow")
summary(coxph)
```

# Model with hyperglycemia and stroke/tia

```r
coxph <- coxph(Surv(time,event) ~ data$hyperglycemia + data$minorstroke, data=data, method="breslow")
summary(coxph)
```

# Otherwise unadjusted model with interaction term of hyperglycemia*minorstroke

```r
coxph <- coxph(Surv(time,event) ~ data$hyperglycemia + data$minorstroke + data$hyperglycemia*data$minorstroke, data=data, method="breslow")
summary(coxph)
```

# Adjusted model including interaction term of stroke/tia*hyperglycemia

```r
coxph <- coxph(Surv(time,event) ~ data$hyperglycemia + data$minorstroke + data$hyperglycemia*data$minorstroke + data$age + data$female + data$black + data$hispanic + data$dapt + data$htn + data$chf + data$af + data$cad + data$valvedisease + data$carotiddisease + data$smoking + data$diabetes, method="breslow")
summary(coxph)
```

# Hyperglycemic group

```r
time <- hyperglycemicgroup$days
event <- hyperglycemicgroup$stroke
event <- as.numeric(event)
coxph <- coxph(Surv(time,event) ~ hyperglycemicgroup$minorstroke + hyperglycemicgroup$age + hyperglycemicgroup$female + hyperglycemicgroup$black + hyperglycemicgroup$hispanic + hyperglycemicgroup$dapt + hyperglycemicgroup$htn + hyperglycemicgroup$chf + hyperglycemicgroup$af + hyperglycemicgroup$cad + hyperglycemicgroup$valvedisease + hyperglycemicgroup$carotiddisease + hyperglycemicgroup$smoking + hyperglycemicgroup$diabetes, method="breslow")
summary(coxph)
```

# Normoglycemic group

```r
time <- normoglycemicgroup$days
event <- normoglycemicgroup$stroke
event <- as.numeric(event)
coxph <- coxph(Surv(time,event) ~ normoglycemicgroup$minorstroke + normoglycemicgroup$age + normoglycemicgroup$female + normoglycemicgroup$black + normoglycemicgroup$hispanic + normoglycemicgroup$dapt + normoglycemicgroup$htn + normoglycemicgroup$chf + normoglycemicgroup$af + normoglycemicgroup$cad + normoglycemicgroup$valvedisease + normoglycemicgroup$carotiddisease + normoglycemicgroup$smoking + normoglycemicgroup$diabetes, method="breslow")
summary(coxph)
```

# Hyperglycemia and Stroke/TIA interaction analysis
# OUTCOME 2 - major hemorrhage

# Major hemorrhage is itt_outcome_type11 in point outcomes
# Time to major hemorrhage is itt_outcome_type11_days in point outcomes

table(hyperglycemicgroup$itt_outcome_type11, hyperglycemicgroup$minorstroke)
table(normoglycemicgroup$itt_outcome_type11, normoglycemicgroup$minorstroke)

# In whole sample - Interaction analysis not possible given 0 hemorrhages in hyperglycemia/minor stroke group

In normoglycemic group - Major hemorrhage/minorstroke-TIA

time <- normoglycemicgroup$itt_outcome_type11_days
event <- normoglycemicgroup$itt_outcome_type11
event <- as.numeric(event)

coxph <- coxph(Surv(time, event) ~ normoglycemicgroup$minorstroke, method="breslow", data=normoglycemicgroup)
summary(coxph)

# Could only adjust for age, sex, race, ethnicity, treatment assignment and hypertension

coxph <- coxph(Surv(time, event) ~ normoglycemicgroup$minorstroke + normoglycemicgroup$age + normoglycemicgroup$female + normoglycemicgroup$black + normoglycemicgroup$hispanic + normoglycemicgroup$dapt + normoglycemicgroup$htn, method="breslow", data=normoglycemicgroup)
summary(coxph)

Hyperglycemia and Stroke/TIA interaction analysis

# OUTCOME 3 - subsequent ischemic stroke, myocardial infarction or vascular death

# Composite is itt_outcome_type1 in point outcomes
# Time to composite is itt_outcome_type1_days in point outcomes

table(hyperglycemicgroup$itt_outcome_type1, hyperglycemicgroup$minorstroke)
table(normoglycemicgroup$itt_outcome_type1, normoglycemicgroup$minorstroke)

# In whole sample

time <- data$itt_outcome_type1_days
event <- data$itt_outcome_type1
event <- as.numeric(event)

coxph <- coxph(Surv(time, event) ~ data$hyperglycemia + data$minorstroke + data$hyperglycemia*data$minorstroke + data$age + data$female + data$black + data$hispanic + data$dapt + data$htn + data$chf + data$af + data$cad + data$valvedisease + data$carotiddisease + data$smoking + data$diabetes, method="breslow")
summary(coxph)

# In hyperglycemic group

time <- hyperglycemicgroup$itt_outcome_type1_days
event <- hyperglycemicgroup$itt_outcome_type1
event <- as.numeric(event)

coxph <- coxph(Surv(time, event) ~ hyperglycemicgroup$minorstroke + hyperglycemicgroup$age + hyperglycemicgroup$female + hyperglycemicgroup$black + hyperglycemicgroup$hispanic + hyperglycemicgroup$dapt + hyperglycemicgroup$htn + hyperglycemicgroup$chf + hyperglycemicgroup$af + hyperglycemicgroup$cad + hyperglycemicgroup$valvedisease + hyperglycemicgroup$carotiddisease + hyperglycemicgroup$smoking + hyperglycemicgroup$diabetes, method="breslow")
summary(coxph)

# In normoglycemic group

time <- normoglycemicgroup$itt_outcome_type1_days
event <- normoglycemicgroup$itt_outcome_type1
event <- as.numeric(event)

coxph <- coxph(Surv(time, event) ~ normoglycemicgroup$minorstroke + normoglycemicgroup$age + normoglycemicgroup$female + normoglycemicgroup$black + normoglycemicgroup$hispanic + normoglycemicgroup$dapt + normoglycemicgroup$htn + normoglycemicgroup$chf + normoglycemicgroup$af +
#10. Subgroup analyses

# Variables used:
# --- data$diabetes - Diabetes mellitus (1=Yes, 0=No)
# --- data$F20Q01 - Adjudicated final etiology (2=minor stroke, 1=TIA)

#10-1 - TIA
#10-2 - minorstroke
#10-5 - Hypergylcemia only (for DAPT)
#10-6 - Normoglycemia only (for DAPT)

#SA 10-1 - Minor stroke only
#1. Create group
#2. Get number of events by creating table
#3. Do survival analysis
#4. Create two groups within (exposed/not exposed) to obtain KM estimates + 95% CI
#5. Plot K-M curves
#6. Add Log Rank test
#7. Make figure (NB include box(lwd=2))
#8. Cox model

#1. Create group
Patients with minor stroke

minorstrokeonly <- data[data$minorstroke == 1,]

#2. Get number of events by creating table
table(minorstrokeonly$stroke, minorstrokeonly$hyperglycemia)

#3. Survival analysis
time <- minorstrokeonly$days
event <- minorstrokeonly$stroke
group <- minorstrokeonly$hyperglycemia
summary(time)
summary(event)
summary(group)
kmsurvival <- survfit(Surv(time,event) ~ 1)
summary(kmsurvival)
plot(kmsurvival)
plot(kmsurvival, fun="event")
kmsurvival <- survfit(Surv(time,event) ~ minorstrokeonly$hyperglycemia)
summary(kmsurvival)
plot(kmsurvival)
plot(kmsurvival, fun="event")

#4. Create two subgroups
#Subgroup 1 - Hyperglycemia in minorstrokeonly
minorstrokeonlyhyperglycemia <- minorstrokeonly[minorstrokeonly$hyperglycemia ==1,]
time <- minorstrokeonlyhyperglycemia$days
event <- minorstrokeonlyhyperglycemia$stroke
event <- as.numeric(event)
kmsurvival <- survfit(Surv(time,event) ~ 1)
summary (kmsurvival)
plot(kmsurvival)
kmsurvivalestimate <- survfit(Surv(time,event) ~ 1)
summary (kmsurvivalestimate, times=90)

#Estimate
1-0.885
#Upper CI
1-0.85
#Lower CI
1-0.921

#Subgroup 2 - Normoglycemia in minorstrokeonly
minorstrokeonlynormoglycemia <- minorstrokeonly[minorstrokeonly$hyperglycemia ==0,]
time <- minorstrokeonlynormoglycemia$days
event <- minorstrokeonlynormoglycemia$stroke
event <- as.numeric(event)
kmsurvival <- survfit(Surv(time,event) ~ 1)
summary (kmsurvival)
plot(kmsurvival)
kmsurvivalestimate <- survfit(Surv(time,event) ~ 1)
summary (kmsurvivalestimate, times=90)

#Estimate
1-0.923
#Upper CI
1-0.911
#Lower CI
1-0.935

#5. Create Kaplan-Meier curves
time <- minorstrokeonly$days
event <- minorstrokeonly$stroke
group <- minorstrokeonly$hyperglycemia
kmsurvival <- survfit(Surv(time,event) ~ group)
summary (kmsurvival)

#6. Add Log Rank test
event <- as.numeric(event)
survdiff(Surv(time,event) ~ group, data=minorstrokeonly)

#7. Make figure (NB include box(lwd=2))
#LARGE GRAPH
plot(kmsurvival, fun="event", col=c("red","blue"), ylim = c(0,1))
box(lwd=2)
axis(side=1, at = c(0,10,20,30,40,50,60,70,80,90), lwd=2)
axis(side=2, at = c(0,0.1,0.2,0.3,0.4,0.5,0.6,0.7,0.8,0.9,1), lwd=2)
#legend("bottomright", c("Normoglycemia (<180mg/dl)", "Hyperglycemia (>180mg/dl)"), col=c("red", "blue"), lty=1)
#---EXPORT TO POWERPOINT

#INSERT
plot(kmsurvival, fun="event", col=c("red","blue"), ylim = c(0,0.15), axes = FALSE, lty=1)
box(lwd=2)
axis(side=1, at = c(0, 30, 60, 90), lwd=2)
axis(side=2, at = c(0,0.01,0.02,0.03,0.04,0.05,0.06,0.07,0.08,0.09,0.1,0.11,0.12,0.13,0.14,0.15), lwd=2)
### Cox model

#### A. Unadjusted Cox model

```r
event <- as.numeric(event)
coxph_unadjusted <- coxph(Surv(time, event) ~ minorstrokeonly$hyperglycemia, method="breslow")
summary(coxph_unadjusted)
```

#### B. Adjusted Cox model (NB minorstroke not included as a covariate but DM included)

```r
coxph_adjusted <- coxph(Surv(time, event) ~ minorstrokeonly$hyperglycemia + minorstrokeonly$age + minorstrokeonly$female + minorstrokeonly$black + minorstrokeonly$hispanic + minorstrokeonly$dapt + minorstrokeonly$htn + minorstrokeonly$chf + minorstrokeonly$af + minorstrokeonly$cad + minorstrokeonly$valvedisease + minorstrokeonly$carotiddisease + minorstrokeonly$smoking + minorstrokeonly$diabetes, method="breslow")
summary(coxph_adjusted)
```

### CLEAR ENVIRONMENT AND RESTART DATASET USING ONLY 2,330 PATIENTS WITH TIA THEN EXCLUDE 3 WITH MISSING GLUCOSE DATA

#### SA 10-2 - TIA only

1. Create group
2. Get number of events by creating table
3. Do survival analysis
4. Create two groups within (exposed/not exposed) to obtain KM estimates + 95% CI
5. Plot K-M curves
6. Add Log Rank test
7. Make figure (NB include box(lwd=2))
8. Cox model

#### Have to re set up dataset and use data$F20Q01[data$F20Q01==1] for the 2,327 patients with TIA

```r
tiaonly <- data[data$F20Q01 == 1,]
tiaonly <- tiaonly[!(is.na(tiaonly$F00Q28)),]
nrow(tiaonly) #3 subjects have been excluded from this analysis
```

#### Survival analysis

```r
time <- tiaonly$days
event <- tiaonly$stroke
group <- tiaonly$hyperglycemia
summary(time)
summary(event)
summary(group)
kmsurvival <- survfit(Surv(time, event) ~ 1)
summary (kmsurvival)
plot(kmsurvival)
plot (kmsurvival, fun="event")
kmsurvival <- survfit(Surv(time, event) ~ tiaonly$hyperglycemia)
```
summary(kmsurvival)
plot(kmsurvival)
plot(kmsurvival, fun="event")

#4. Create two subgroups
#Subgroup 1 - Hyperglycemia in tiaonly
tiaonlyhyperglycemia <- tiaonly[tiaonly$hyperglycemia ==1,]
time <- tiaonlyhyperglycemia$days
event <- tiaonlyhyperglycemia$stroke
event <- as.numeric(event)
kmsurvival <- survfit(Surv(time, event) ~ 1)
summary(kmsurvival)
plot(kmsurvival)
kmsurvivalestimate <- survfit(Surv(time, event) ~ 1)
summary(kmsurvivalestimate, times=90)

#Estimate
1-0.935
#Upper CI
1-0.902
#Lower CI
1-0.97

#Subgroup 2 - Normoglycemia in tiaonly
tiaonlynormoglycemia <- tiaonly[tiaonly$hyperglycemia ==0,]
time <- tiaonlynormoglycemia$days
event <- tiaonlynormoglycemia$stroke
event <- as.numeric(event)
kmsurvival <- survfit(Surv(time, event) ~ 1)
summary(kmsurvival)
plot(kmsurvival)
kmsurvivalestimate <- survfit(Surv(time, event) ~ 1)
summary(kmsurvivalestimate, times=90)

#Estimate
1-0.974
#Upper CI
1-0.967
#Lower CI
1-0.981

#5. Create Kaplan-Meier curves
time <- tiaonly$days
event <- tiaonly$stroke
group <- tiaonly$hyperglycemia
kmsurvival <- survfit(Surv(time, event) ~ group)
summary(kmsurvival)

#6. Add Log Rank test
event <- as.numeric(event)
survdiff(Surv(time, event) ~ group, data=tiaonly)

#7. Make figure (NB include box(lwd=2))
#LARGE GRAPH
plot(kmsurvival, fun="event", col=c("red","blue"), ylim = c(0,1))
box(lwd=2)
axis(side=1, at = c(0,10,20,30,40,50,60,70,80,90), lwd=2)
axis(side=2, at = c(0,0.1,0.2,0.3,0.4,0.5,0.6,0.7,0.8,0.9,1), lwd=2)
#dlegend("bottomright", c("Normoglycemia (<180mg/dl)", "Hyperglycemia (>180mg/dl)"), col=c("red", "blue"), lty=1)
#---EXPORT TO POWERPOINT
#INSERT
plot(kmsurvival, fun="event", col=c("red","blue"), ylim = c(0,0.15), axes = FALSE, lty=1)
box(lwd=2)
axis(side=1, at = c(0, 30, 60, 90), lwd=2)
axis(side=2, at = c(0,0.01,0.02,0.03,0.04,0.05,0.06,0.07,0.08,0.09,0.1,0.11,0.12,0.13,0.14,0.15), lwd=2)
#legend("bottomright", c("SAPT", "DAPT"), col=c("red", "blue"), lty=1)
#---EXPORT TO POWERPOINT

#8. Cox model
#A. Unadjusted Cox model
event <- as.numeric(event)
coxph <- coxph(Surv(time,event) ~ tiaonly$hyperglycemia, method="breslow")
summary(coxph)

#B. Adjusted Cox model (NB minorstroke not included as a covariate but DM included)
#WITH DIABETES
coxph <- coxph(Surv(time,event) ~ tiaonly$hyperglycemia + tiaonly$age + tiaonly$female + tiaonly$black +
tiaonly$hispanic + tiaonly$dapt + tiaonly$htn + tiaonly$chf + tiaonly$af + tiaonly$ht + tiaonly$valvedisease +
tiaonly$carotiddisease + tiaonly$smoking + tiaonly$diabetes, method="breslow")
summary(coxph)

########################################################################
########################################################################
### RE SET-UP DATASET FROM BEGINNING SKIPPING OVER PREVIOUS SECTION

#SA 10-3 - DAPT EFFECT in hyperglycemia
#1. Create group
#2. Get number of events by creating table
#3. Do survival analysis
#4. Create two groups within (exposed/not exposed) to obtain KM estimates + 95% CI
#5. Plot K-M curves
#6. Add Log Rank test
#7. Make figure (NB include box(lwd=2))
#8. Cox model

#For analysis of DAPT effects in those with/without hyperglycemia
#1. Create group
hyperglycemicgroup <- data[data$hyperglycemia ==1,]
#2. Get number of events by creating table (first term is on x axis, second term is on y axis)
table(hyperglycemicgroup$stroke, hyperglycemicgroup$dapt)
#3. Do survival analysis
time <- hyperglycemicgroup$days
event <- hyperglycemicgroup$stroke
group <- hyperglycemicgroup$dapt
summary(time)
summary(event)
summary(group)
kmsurvival <- survfit(Surv(time,event) ~ 1)
summary (kmsurvival)
plot(kmsurvival)
plot(kmsurvival, fun="event")
kmsurvival <- survfit(Surv(time,event) ~ group)
summary (kmsurvival)
plot(kmsurvival)
plot(kmsurvival, fun="event")

#4. Create two groups within (exposed/not exposed) to obtain KM estimates + 95% CI

#4A. DAPT + Hyperglycemia group
dapthyperglycemia <- hyperglycemicgroup[hyperglycemicgroup$dapt ==1,]
time <- dapthyperglycemia$days
event <- dapthyperglycemia$stroke
event <- as.numeric(event)
kmsurvival <- survfit(Surv(time,event) ~ 1)
summary (kmsurvival)
plot(kmsurvival)
kmsurvivalestimate <- survfit(Surv(time,event) ~ 1)
summary (kmsurvivalestimate, times=90)

#Estimate
1-0.895
#Upper CI
1-0.861
#Lower CI
1-0.932

#4B. SAPT + Hyperglycemia group
sapthyperglycemia <- hyperglycemicgroup[hyperglycemicgroup$dapt ==0,]
time <- sapthyperglycemia$days
event <- sapthyperglycemia$stroke
event <- as.numeric(event)
kmsurvival <- survfit(Surv(time,event) ~ 1)
summary (kmsurvival)
plot(kmsurvival)
kmsurvivalestimate <- survfit(Surv(time,event) ~ 1)
summary (kmsurvivalestimate, times=90)

#Estimate
1-0.911
#Upper CI
1-0.877
#Lower CI
1-0.946

#5. Plot Kaplan-Meier Curves:
time <- hyperglycemicgroup$days
event <- hyperglycemicgroup$stroke
group <- hyperglycemicgroup$dapt
kmsurvival <- survfit(Surv(time,event) ~ group)
summary (kmsurvival)
plot(kmsurvival, fun="event")
#LARGE GRAPH
plot(kmsurvival, fun="event", col=c("red","blue"), ylim=c(0,1))
box(lwd=2)
axis(side=1, at=c(0,10,20,30,40,50,60,70,80,90), lwd=2)
axis(side=2, at=c(0,0.1,0.2,0.3,0.4,0.5,0.6,0.7,0.8,0.9,1), lwd=2)
dlegend("bottomright", c("Normoglycemia (<180mg/dl)" , "Hyperglycemia (>180mg/dl)"), col=c("red", "blue"), lty=1)
#---EXPORT TO POWERPOINT
#INSERT
plot(kmsurvival, fun="event", col=c("red","blue"), ylim=c(0,0.15), axes = FALSE, lty=1)
box(lwd=2)
axis(side=1, at=c(0,30,60,90), lwd=2)
axis(side=2, at=c(0,0.01,0.02,0.03,0.04,0.05,0.06,0.07,0.08,0.09,0.1,0.11,0.12,0.13,0.14,0.15), lwd=2)
legend("bottomright", c("SAPT", "DAPT"), col=c("red", "blue"), lty=1)
#---EXPORT TO POWERPOINT
#6. Log Rank Test to compare curve and add as annotation to figure - NB event has to be numeric and not a factor
event <- as.numeric(event)
survdiff(Surv(time,event) ~ group, data=hyperglycemicgroup)
#7. Optimize in powerpoint
#8. Proportional Hazards Regression Modelling
#A. Unadjusted Cox model
time <- hyperglycemicgroup$days
event <- hyperglycemicgroup$stroke
group <- hyperglycemicgroup$dapt
event <- as.numeric(event)
coxph <- coxph(Surv(time,event) ~ group, method="breslow")
summary(coxph)
#B. Adjusted Cox model
#Maybe don't do for DAPT vs. SAPT comparisons
coxph <- coxph(Surv(time,event) ~ hyperglycemicgroup$dapt + hyperglycemicgroup$age + hyperglycemicgroup$female
+ hyperglycemicgroup$black + hyperglycemicgroup$minorstroke + hyperglycemicgroup$hispanic +
hyperglycemicgroup$htn + hyperglycemicgroup$chf + hyperglycemicgroup$af + hyperglycemicgroup$cad +
hyperglycemicgroup$valvedisease + hyperglycemicgroup$carotiddisease + hyperglycemicgroup$smoking +
hyperglycemicgroup$diabetes, method="breslow")
summary(coxph)

#SA 10-4 - DAPT EFFECT in normoglycemia
#1. Create group
#2. Get number of events by creating table
#3. Do survival analysis
#4. Create two groups within (exposed/not exposed) to obtain KM estimates + 95% CI
#5. Plot K-M curves
#6. Add Log Rank test
#7. Make figure (NB include box(lwd=2))
#8. Cox model
#1. Create group:
normoglycemicgroup <- data[data$hyperglycemia == 0,]
#2. Get number of events by creating table (first term is on x axis, second term is on y axis)
table(normoglycemicgroup$stroke, normoglycemicgroup$dapt)
#3. Do survival analysis
time <- normoglycemicgroup$days
event <- normoglycemicgroup$stroke
group <- normoglycemicgroup$dapt
summary(time)
summary(event)
summary(group)
kmsurvival <- survfit(Surv(time, event) ~ 1)
summary (kmsurvival)
plot(kmsurvival)
plot(kmsurvival, fun="event")
kmsurvival <- survfit(Surv(time, event) ~ group)
summary (kmsurvival)
plot(kmsurvival)
plot(kmsurvival, fun="event")

#4. Create two groups within (exposed/not exposed) to obtain KM estimates + 95% CI
#4A. DAPT + Normoglycemia group
daptnormoglycemia <- normoglycemicgroup[normoglycemicgroup$dapt == 1,]
time <- daptnormoglycemia$days
event <- daptnormoglycemia$stroke
event <- as.numeric(event)
kmsurvival <- survfit(Surv(time, event) ~ 1)
summary (kmsurvival)
plot(kmsurvival)
kmsurvivalestimate <- survfit(Surv(time, event) ~ 1)
summary (kmsurvivalestimate, times=90)

#Estimate
1-0.96
#Upper CI
1-0.951
#Lower CI
1-0.968

#4B. SAPT + Normoglycemia group
.saptnormoglycemia <- normoglycemicgroup[normoglycemicgroup$dapt == 0,]
time <- .aptnormoglycemia$days
event <- .aptnormoglycemia$stroke
event <- as.numeric(event)
kmsurvival <- survfit(Surv(time, event) ~ 1)
summary (kmsurvival)
plot(kmsurvival)
kmsurvivalestimate <- survfit(Surv(time, event) ~ 1)
summary (kmsurvivalestimate, times=90)

#Estimate
1-0.937
#Upper CI
1-0.927
#Lower CI
1-0.948

#5. Plot K-M curves
time <- normoglycemicgroup$days
```r
event <- normoglycemicgroup$stroke
group <- normoglycemicgroup$dapt
kmsurvival <- survfit(Surv(time,event) ~ group)
summary (kmsurvival)
plot(kmsurvival, fun="event")

#6. Add Log Rank test
event <- as.numeric(event)
survdiff(Surv(time,event) ~ group, data=normoglycemicgroup)

#7. Make figure (NB include box(lwd=2))
#LARGE GRAPH
plot(kmsurvival, fun="event", col=c("red","blue"), ylim = c(0,1))
box(lwd=2)
axis(side=1, at = c(0,10,20,30,40,50,60,70,80,90), lwd=2)
axis(side=2, at = c(0,0.1,0.2,0.3,0.4,0.5,0.6,0.7,0.8,0.9,1), lwd=2)
legend("bottomright", c("Normoglycemia (<180mg/dl)", "Hyperglycemia (>180mg/dl)"), col=c("red", "blue"), lty=1)

#---EXPORT TO POWERPOINT
#INSERT
plot(kmsurvival, fun="event", col=c("red","blue"), ylim = c(0,0.15), axes = FALSE, lty=1)
box(lwd=2)
axis(side=1, at = c(0, 30, 60, 90), lwd=2)
axis(side=2, at = c(0,0.01,0.02,0.03,0.04,0.05,0.06,0.07,0.08,0.09,0.1,0.11,0.12,0.13,0.14,0.15), lwd=2)
legend("bottomright", c("SAPT", "DAPT"), col=c("red", "blue"), lty=1)

#---EXPORT TO POWERPOINT

#8. Cox model
#B. Unadjusted Cox model
event <- as.numeric(event)
coxph <- coxph(Surv(time,event) ~ group, method="breslow")
summary(coxph)

#Adjusted Cox model
#Will not do it for this one as it is for DAPT/SAPT
#coxph <- coxph(Surv(time,event) ~ normoglycemicgroup$dapt + normoglycemicgroup$age +
normoglycemicgroup$female + normoglycemicgroup$black + normoglycemicgroup$hispanic +
normoglycemicgroup$minorstroke + normoglycemicgroup$hln + normoglycemicgroup$chf + normoglycemicgroup$af +
normoglycemicgroup$cad + normoglycemicgroup$valvedisease + normoglycemicgroup$carotiddisease +
normoglycemicgroup$smoking + normoglycemicgroup$diabetes, method="breslow")
#summary(coxph)

#11. Sensitivity analyses
#11.1 Glucose as continuous variable
#Base model assuming linear relationship between glucose and the hazard of subsequent stroke
#UNADJUSTED
time <- data$days
event <- data$stroke
event <- as.numeric(event)
survival <- Surv(time,event)
coxph <- coxph(survival ~ data$glucose, method="breslow")
summary(coxph)

#ADJUSTED
```

coxph <- coxph(survival ~ data$glucose + data$age + data$female + data$black + data$hispanic + data$dapt + data$minorstroke + data$htn + data$chf + data$af + data$cad + data$valvedisease + data$carotid + data$smoking + data$diabetes, method="breslow")
summary(coxph)
rsq(coxph)

# Checking proportional hazards assumption
fit.coxph_zph <- cox.zph(coxph)
fit.coxph_zph
plot(fit.coxph_zph, var="data$glucose")

# Transform glucose as restricted cubic spline (5 knots between 0-1)
rcs_glucose <- rcs(data$glucose, quantile(data$glucose, c(0, .05, .275, .5, .725, .95, 1)))
rcscoxph <- coxph(survival ~ rcs_glucose + data$age + data$female + data$black + data$hispanic + data$dapt + data$minorstroke + data$htn + data$chf + data$af + data$cad + data$valvedisease + data$carotid + data$smoking + data$diabetes, method="breslow")
summary(rcscoxph)

# likelihood ratio test for linearity
anova(coxph, rcscoxph, test="Chisq")

# Figure 2 - plot of hazard of ischemic stroke vs serum blood glucose

# Transform glucose as restricted cubic spline (5 knots between 0-1)
#11.2. Propensity score matched analysis

data$hyperglycemia <- as.numeric(data$hyperglycemia)

psmodel <- glm(data$hyperglycemia ~ data$age + data$female + data$black + data$hispanic + data$dapt +
data$minorstroke + data$htn + data$chf + data$af + data$cad + data$valvedisease + data$carotiddisease +
data$smoking + data$diabetes, family=binomial, data=data)

summary(psmodel)

pscore <- psmodel$fitted.values

#Comparing characteristics before and after matching/PSM diagnostics

m.out <- matchit(data$hyperglycemia ~ data$age + data$female + data$black + data$hispanic + data$dapt +
data$minorstroke + data$htn + data$chf + data$af + data$cad + data$valvedisease + data$carotiddisease +
data$smoking + data$diabetes, family=binomial, data=data, caliper = 0.05, method = "nearest")

summary(m.out)

plot(m.out,type="hist")

plot(summary(m.out), xlim=c(0,2))

#Creating new object containing two matched groups

match1 <- match.data(m.out)

#Kaplan-Meier curves comparing propensity score-matched groups

time <- match1$days

event <- match1$stroke

group <- match1$hyperglycemia

summary(time)

summary(event)

summary(group)

kmsurvival <- survfit(Surv(time,event) ~ group)

summary(kmsurvival)

plot(kmsurvival)

#LARGE GRAPH

plot(kmsurvival, fun="event", col=c("red","blue"), ylim = c(0,1))

axis(side=1, at = c(0,10,20,30,40,50,60,70,80,90))

axis(side=2, at = c(0,0.1,0.2,0.3,0.4,0.5,0.6,0.7,0.8,0.9,1))

legend("bottomright", c("Normoglycemia (<180mg/dl)" ,"Hyperglycemia (>180mg/dl)" ), col=c("red", "blue"), lty=1)

#INSERT

plot(kmsurvival, fun="event", col=c("red","blue"), ylim = c(0,0.15), axes = TRUE)

axis(side=1, at = c(0,10, 20, 30, 40, 50, 60, 70, 80, 90))

axis(side=2, at = c(0,0.01,0.02,0.03,0.04,0.05,0.06,0.07,0.08,0.09,0.1,0.11,0.12,0.13,0.14,0.15))

legend("bottomright", c("Normoglycemia (<180mg/dl)" ,"Hyperglycemia (>180mg/dl)" ), col=c("red", "blue"), lty=1)

#Add in proportional hazards regression modelling

event <- as.numeric(event)

coxph <- coxph(Surv(time,event) ~ group, method="breslow")

summary(coxph)

#12. Final Sensitivity Analysis - Replacing final adjudicated etiology with infarct on imaging

#Infarct on imaging attributable to index event
```r
data$F20Q04
str(data$F20Q04)
sum(is.na(data$F20Q04)==FALSE)
sum(is.na(data$F20Q04)==TRUE)

# 5 subjects missing data on imaging attributable to index event

time <- data$days
event <- data$stroke
event <- as.numeric(event)
coxph <- coxph(Surv(time,event) ~ data$hyperglycemia + data$age + data$female + data$black + data$hispanic +
data$dapt + data$F20Q04 + data$htn + data$chf + data$af + data$cad + data$valvedisease + data$carotiddisease +
data$smoking + data$diabetes, method="breslow")
summary(coxph)
```
Table S1. Proportional hazards regression models performed separately in patients with and without hyperglycemia. The interaction term is derived from a model including all patients in the study sample including the term (hyperglycemia*final adjudicated etiology). Hazard ratios are for the association between minor stroke and the endpoint within the <180mg/dl and ≥180mg/dl strata.

| Outcome                  | Minor stroke (n=2,304) | TIA/Other (n=2,574) | HR (95% CI)       | P-value | P-value for interaction |
|--------------------------|------------------------|---------------------|------------------|---------|-------------------------|
| **Ischemic Stroke**      |                        |                     |                  |         |                         |
| <180mg/dl                | 147/1,967              | 66/2,317            | 2.83 (2.11-3.80)^a | <0.001  |                         |
| ≥180mg/dl                | 37/337                 | 17/257              | 1.84 (1.01-3.33)^a | 0.04    |                         |
| **Major Hemorrhage**     |                        |                     |                  |         |                         |
| <180mg/dl                | 15/1,967               | 16/2,317            | 1.18 (0.58-2.39)^b | 0.65    |                         |
| ≥180mg/dl                | 0/337                  | 2/257               | -                | -       |                         |
| **Primary Endpoint**c    |                        |                     |                  |         |                         |
| <180mg/dl                | 152/1,967              | 71/2,317            | 2.71 (2.04-3.60)^a | <0.001  |                         |
| ≥180mg/dl                | 40/337                 | 18/257              | 1.90 (1.07-3.38)^a | 0.03    |                         |

a. Adjusted for age, sex, race, ethnicity, treatment assignment, hypertension, congestive cardiac failure, atrial fibrillation, coronary artery disease, valve disease, carotid disease, smoking and diabetes.
b. Adjusted for age, sex, race, ethnicity, treatment assignment and hypertension.
c. Subsequent ischemic stroke, myocardial infarction, ischemic vascular death.
Figure S1. Propensity-scores across hyperglycemic and normoglycemic subgroups before (LEFT PANELS) and after (RIGHT PANELS) the matching procedure.